

# 1 Severe disease is not essential for a high neutralizing 2 antibody response post-SARS-CoV-2 infection

3

4 Afrah Khairallah<sup>1</sup>, Zesuliwe Jule<sup>1</sup>, Alice Piller<sup>1</sup>, Mallory Bernstein<sup>1</sup>, Kajal Reedy<sup>1</sup>,  
5 Yashica Ganga<sup>1</sup>, Bernadett I. Gosnell<sup>2</sup>, Farina Karim<sup>1</sup>, Yunus Moosa<sup>2</sup>, Thumbi  
6 Ndung'u<sup>1,3,4,5</sup>, Khadija Khan<sup>1</sup>, Alex Sigal<sup>1,6</sup>

7 <sup>1</sup>Africa Health Research Institute and University of KwaZulu-Natal, Durban, South Africa. <sup>2</sup>Department  
8 of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, University of KwaZulu-Natal,  
9 Durban, South Africa. <sup>3</sup>HIV Pathogenesis Programme, University of KwaZulu-Natal, Durban, South  
10 Africa. <sup>4</sup>Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and  
11 Harvard University, Cambridge, MA, USA. <sup>5</sup>Division of Infection and Immunity, University College  
12 London, London, UK. <sup>6</sup>The Lautenberg Center for Immunology and Cancer Research, Faculty of  
13 Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

14

15 **Neutralizing antibody responses correlate with protection from SARS-CoV-2 infection,**  
16 **yet higher neutralizing responses associate with more severe disease. Whether people**  
17 **without severe disease can also develop strong neutralizing responses to infection,**  
18 **and the pathways involved, is less clear. We performed a proteomic analysis on sera**  
19 **from 71 individuals infected with ancestral SARS-CoV-2, enrolled during the first South**  
20 **African infection wave. We determined disease severity by whether participants**  
21 **required supplemental oxygen and measured neutralizing antibody levels at**  
22 **convalescence. High neutralizing antibodies were associated with high disease**  
23 **severity, yet 40% of participants with lower disease severity had neutralizing antibody**  
24 **levels comparable to those with severe disease. We found 130 differentially expressed**  
25 **proteins between high and low neutralizers and 40 between people with high versus**  
26 **low disease severity. Five proteins overlapped, including furin, a protease which**  
27 **enhances SARS-CoV-2 infection. High neutralizers with non-severe disease had similar**  
28 **levels of differentially expressed neutralization response proteins to high neutralizers**  
29 **with severe disease, yet similar levels of differentially expressed disease severity**  
30 **proteins to participants with non-severe disease. Furthermore, we could reasonably**  
31 **predict who developed a strong neutralizing response based on a single protein,**  
32 **HSPA8, involved in clathrin pit uncoating. These results indicate that a strong antibody**  
33 **response does not always require severe disease and may involve different pathways.**

34

## 35 Introduction

36 Many transient viral infections elicit a neutralizing antibody response which not only helps to  
37 clear the virus, but also protects convalescent individual from re-infection<sup>1</sup>. This has been  
38 shown for SARS-CoV-2, and until the Omicron variant emerged, re-infection was rare<sup>2</sup>.  
39 Binding of neutralizing antibodies prevents the viral spike protein from accessing the  
40 angiotensin-converting enzyme 2 (ACE2) viral receptor<sup>3</sup>. Neutralizing antibody levels strongly  
41 correlate with the degree of vaccine mediated protection<sup>4-7</sup>.

42 Factors predisposing to higher disease severity and mortality in Covid-19 include male sex,  
43 diabetes, hypertension, and HIV<sup>22</sup>. Higher disease severity results in higher neutralizing  
44 antibody levels in SARS-CoV-2 infection<sup>8-19</sup>. In contrast, asymptomatic infection associates

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

45 with a low neutralizing antibody response<sup>20,21</sup>. This opens the question of whether severe  
46 disease is necessary for a robust antibody response. An alternative is that both are driven by  
47 shared factors such as high viral titers or prolonged infection<sup>23</sup>. Given that severe Covid-19 is  
48 due to lower respiratory tract infection, which causes acute respiratory distress syndrome  
49 (ARDS) from aberrant inflammation interfering with gas exchange<sup>24,25</sup>, it is possible that a more  
50 controlled immune response could avoid ARDS while still being sufficiently robust to elicit high  
51 neutralizing antibody levels.

52 Here, we asked whether severe Covid-19 is required for high neutralizing antibody levels post-  
53 infection. To avoid confounding the results with re-infection and vaccination, we selected  
54 individuals from our cohort<sup>26</sup> who were infected by ancestral SARS-CoV-2 in the first Covid-  
55 19 infection wave in South Africa, before vaccination was available and variants arose. Given  
56 the rarity of reinfection pre-Omicron<sup>27</sup>, the infections we studied were very likely first exposures  
57 to SARS-CoV-2. We separated participants with Covid-19 into higher severity versus lower  
58 severity by whether participants required supplemental oxygen. The requirement for  
59 supplemental oxygen is a key measure in ordinal scales like that used by the World Health  
60 Organization<sup>28</sup>. We used proteomics to examine the differentially regulated proteins and  
61 pathways in people with different combinations of disease severity and antibody response.

62 We observed that, while higher severity cases tended to make strong antibody responses, a  
63 subset of participants with more mild disease who did not require supplemental oxygen also  
64 showed high neutralizing antibody levels. There was minor overlap between the differentially  
65 expressed proteins associated with severity versus those associated with the neutralizing  
66 antibody response. Additionally, levels of heat shock protein family A member 8 (HSPA8)  
67 emerged as predictive of neutralizing responses.

68

## 69 **Results**

### 70 **Cohort characteristics**

71 We enrolled 72 participants infected during the first SARS-CoV-2 infection wave in Durban  
72 South Africa lasting from March to October 2020<sup>29</sup> (Figure 1, Table 1). One participant in the  
73 cohort had immunosuppression due to advanced HIV disease with a CD4 count of 6 at  
74 enrollment and an HIV viral load of 34,151 copies/mL. This participant did not make a  
75 neutralizing antibody response and had persistent SARS-CoV-2 infection, as described in our  
76 previous work<sup>29-31</sup>. Because of the outlier immune state, we excluded this participant from  
77 further analysis and analyzed results for 71 participants.

78 We scored disease severity by whether the participant required supplemental oxygen<sup>26,28</sup>.  
79 Participants were classified into the less severe (no supplemental oxygen) and more severe  
80 (supplemental oxygen) groups. For brevity, we refer to these groups as “non-severe” and  
81 “severe”, although we recognize there may be gradations of severity within each group.  
82 Demographics and comorbidities were recorded. We determined HIV status, HIV viral load,  
83 and CD4 T cell concentrations in the blood. Diagnosis of SARS-CoV-2 infection was performed  
84 by qPCR. Participants were enrolled a median of 6 days (IQR 4-8 days) post-diagnosis. A  
85 quantitative SARS-CoV-2 titer was not available. We performed the first sampling at  
86 enrollment (Figure 1). This sample was used for proteomic analysis as well as to measure  
87 lymphocytes, neutrophils, CD4 T cell numbers, HIV status, and HIV viral load.

88 A second sample was taken a median of 32 days (IQR 17-35 days) post-diagnosis, at a time  
89 when the infection elicited antibody response should be close to its peak<sup>16</sup>. This sample was  
90 used to measure neutralizing antibody levels by a live virus focus reduction neutralization test

91 (FRNT<sup>32,33</sup>). Fifty-five participants (76%) were determined to have non-severe disease  
92 because they did not require supplemental oxygen, and 17 (24%) were classified as severe.  
93 People living with HIV (PLWH) accounted for 47% of the participants, reflecting the high HIV  
94 prevalence in the province of KwaZulu-Natal in South Africa where Durban is located<sup>34</sup>.

95 CD4 T cell count was a median of 590 cells/ $\mu$ L (IQR 340-940) at enrollment over the entire  
96 participant group and was significantly lower ( $p=0.0072$  by the Mann-Whitney U test, Table 1)  
97 in the severe (380 cells/ $\mu$ L, IQR 270-590) relative to the non-severe (700 cells/ $\mu$ L, IQR 470-  
98 1100) group. The lower CD4 count in severe disease is expected because severe disease  
99 often results in lymphopenia<sup>35-37</sup>. The CD4 count increased upon convalescence at the second  
100 visit to a median of 830 cells/ $\mu$ L (IQR 510-1100), and there was no significant difference  
101 between the severe (820 cells/ $\mu$ L, IQR 530-1100) and non-severe (840 cells/ $\mu$ L, IQR 390-900)  
102 groups (Table 1).

103 Increased neutrophils are associated with severe disease<sup>26,37-39</sup> and the neutrophil to  
104 lymphocyte ratio (NLR) was significantly higher in the severe group in the first visit (4.2 vs.  
105 1.9,  $p=0.04$  by the Mann-Whitney U test, see Table 1). The NLR dropped and was similar in  
106 both groups at the second, convalescence visit (Table 1). The severe group had significantly  
107 higher levels of neutralizing antibodies, as measured by the FRNT<sub>50</sub>, which is the inverse  
108 serum dilution in the FRNT assay required to neutralize 50% of ancestral SARS-CoV-2 (Table  
109 1).

110

#### 111 Categorization of participants into high and low neutralizers and association with risk factors

112 We used the median FRNT<sub>50</sub> neutralization level (FRNT<sub>50</sub>=358) to categorize participants into  
113 high and low neutralizers. Our justification for using the median is that it is simple yet gives  
114 two groups which are strongly distinct in neutralization capacity: Geometric mean titer (GMT)  
115 FRNT<sub>50</sub> values were 1348 in the high neutralizer group ( $n=35$ ) versus 46 in the low neutralizer  
116 group ( $n=36$ ), a 29-fold drop (Figure 2A). The number of participants in the non-severe disease  
117 group was 55, out of which 33 were low neutralizers, while 22 were high neutralizers (Table  
118 2). Out of the 16 participants in the high severity group, 13 were high neutralizers while the  
119 remaining 3 were low neutralizers (Table 2).

120

121 The frequency of participants with high disease severity was significantly higher in the high  
122 neutralization group relative to the low neutralization group ( $p=0.0046$  by Fisher's Exact test,  
123 Figure 2B). However, as presented in Table 2, the majority of the 35 participants in the high  
124 neutralizer group were non-severe (22 participants, versus 13 with high severity). There was  
125 no significant difference in neutralizing antibody levels between participants with high disease  
126 severity and high neutralizers with low disease severity (Figure S1).

127

128 High NLR, comorbidities, and being male was associated with higher neutralization in  
129 univariate analysis. The frequency of individuals with high NLR ( $>6$ )<sup>38</sup>, was significantly higher  
130 in the high neutralization group ( $p=0.011$  by Fisher's Exact test, Figure 2C). The frequency of  
131 individuals with recorded comorbidities (hypertension and/or diabetes) was also significantly  
132 higher in the high neutralizer group ( $p=0.00018$  by Fisher's Exact test, Figure 2D). Males were  
133 significantly more frequent among the high neutralizers ( $p=0.042$  by Fisher's Exact test, Figure  
134 2E). In contrast, there was no significant difference between the frequency of PLWH versus  
135 HIV negative people between the high and low neutralizer groups (Figure 2F). Univariate  
136 analysis showed significantly increased odds (odds ratio (OR)  $>1$ ) of being a high neutralizer  
137 with severe disease, comorbidities, high NLR, and being male (Figure 2G). In multivariate  
138 analysis, only severe disease and comorbidities remained significant (Figure 2H, with exact

139 numbers and confidence intervals in Table S1). People who both required supplemental  
140 oxygen and had comorbidities appeared only in the high neutralizer group (Figure S2).  
141 However, the largest subgroup in the high neutralizer group consisted of people with non-  
142 severe disease without comorbidities (Figure S2).

143

#### 144 Differentially expressed proteins between high and low neutralizers

145

146 We used SomaScan proteomics<sup>40</sup> to determine the levels of ~5000 proteins in participant  
147 plasma from the blood sample collected at enrollment. Differentially expressed proteins  
148 (DEPs) were identified as those with a  $\geq 1.5$ -fold decrease or increase in mean expression in  
149 one group relative to the other, with a p-value corrected by the false discovery rate (FDR) of  
150  $< 0.05$ <sup>41-43</sup>. We obtained 130 significant DEPs when comparing the high versus the low  
151 neutralizer groups (Figure 3A) and 40 DEPs when comparing the non-severe versus the  
152 severe disease groups (Figure 3B).

153

154 Examples of DEPs with higher levels in high versus low neutralizers (Figure 3A) included  
155 HSPA8, also called HSC70<sup>44</sup>. This protein is a chaperone from the HSP70 family of  
156 constitutively expressed heat shock proteins and has multiple functions including clathrin  
157 uncoating during clathrin-mediated endocytosis<sup>45</sup>, antigen presentation on MHC class II  
158 molecules<sup>44,46</sup>, and autophagy<sup>44</sup>. It interacts with proteins from multiple viruses, including the  
159 SARS-CoV-2 spike<sup>47</sup>, the influenza M1<sup>48</sup>, and the papillomavirus L2<sup>49</sup> proteins. Another DEP  
160 with significantly higher levels in high neutralizers was von Willebrand factor (VWF), involved  
161 in orchestrating the coagulation response<sup>47</sup>.

162

163 Furin was an example of a significant DEP in severe versus non-severe disease (Figure 3B).  
164 Furin is a protease which promotes SARS-CoV-2 cellular infection by cleaving the S1/S2  
165 polybasic site and therefore facilitating viral fusion<sup>50</sup>. Furin was also elevated in high versus  
166 low neutralizers. Another infection promoting factor with higher levels in the high disease  
167 severity group was Calpain-2 (CAPN2), involved in positively regulating the cell surface levels  
168 of the ACE2 receptor<sup>51</sup>.

169

170 Only five DEPs were found to overlap between the neutralization and disease severity  
171 conditions (Figure 3C, proteins marked in green in Figure 3A-B). Upregulated DEPs in  
172 common to both high neutralization and high disease severity were furin, DNase1L2, and  
173 endoplasmic reticulum protein 44 (Erp44). Downregulated DEPs in common were anthrax  
174 toxin receptor-2 (ANTXR2) and amyloid beta precursor like protein 1 (APLP1). DNase1L2 has  
175 been shown to be transcriptionally activated by inflammatory cytokines<sup>52</sup> resulting from  
176 infection. Erp44, a protein from the thioredoxin family, is upregulated by endoplasmic reticulum  
177 stress<sup>53</sup> and has been reported to be a target of SARS-CoV-2 ORF8<sup>54</sup>. ANTXR2, the receptor  
178 for the anthrax toxin, is involved in angiogenesis and cell adhesion<sup>55</sup>. APLP1 is required for  
179 glucose homeostasis<sup>56</sup>, and its downregulation is associated with neurological symptoms of  
180 Covid-19<sup>57</sup>.

181

#### 182 Gene set enrichment analysis of differentially regulated pathways in neutralization and disease 183 severity

184

185 We used Gene Set Enrichment Analysis (GSEA)<sup>58</sup> to determine the differentially regulated  
186 pathways between high and low neutralizers and participants with severe versus non-severe  
187 disease (Figure 4). We used the Molecular Signatures Database (MSigDB) Hallmark gene  
188 set<sup>59</sup> and a significance threshold of FDR  $< 0.1$  to determine significantly enriched pathways.

189 We found 7 upregulated pathways and 1 downregulated pathway in high versus low  
190 neutralizers. We found 4 upregulated pathways and 1 downregulated pathway in severe  
191 versus non-severe participants. There was one upregulated pathway in common.

192  
193 In high neutralizers, the upregulated pathways were adipogenesis, the interferon- $\alpha$  (IFN- $\alpha$ )  
194 response, PI3k/Akt/mTOR signaling, oxidative phosphorylation, mTORC1 signaling, and  
195 xenobiotic metabolism. The downregulated pathway was hedgehog signaling. The pathways  
196 upregulated in the high versus low severity groups were glycolysis, the UV response, and the  
197 unfolded protein response. Spermatogenesis was downregulated. Similarly to analysis of  
198 individual DEPs, there was no extensive overlap in the pathways between responses. The  
199 single pathway upregulated in common between the high versus low neutralizers and severe  
200 versus non-severe disease was fatty acid metabolism.

201  
202 High neutralizers showed similar DEP levels regardless of severity

203  
204 To better understand differences between high neutralizers with severe versus non-severe  
205 disease, we examined the top 20 most significant by FDR DEPs in the neutralization response  
206 to determine whether they are similarly or differently regulated in high neutralizers with high  
207 versus low disease severity (Figure 5). They included fibroblast activation protein- $\alpha$  (FAP), a  
208 serine protease involved in tissue remodeling<sup>60</sup>, motilin (MLN), a hormone promoting  
209 gastrointestinal motility<sup>61</sup>, and ribosome-binding protein 1 (RRBP1), involved in the  
210 endoplasmic reticulum stress response<sup>62</sup>.

211  
212 In 14 of these DEPs including FAP, MLN, and RRBP1, levels were not significantly different  
213 between high neutralizers with non-severe disease and high neutralizers with severe disease.  
214 Both groups had a significantly different level of DEPs relative to the low neutralizer group  
215 (Figure 5). For the remaining six proteins, the high neutralizer group with non-severe disease  
216 displayed intermediate expression, between high neutralizers with severe disease and the low  
217 neutralizers. This group included 3 of the 5 proteins which were in common between the  
218 neutralization response and disease severity (furin, ANTXR2, and DNase1L2), as well as  
219 VWF and HSPA8. These results indicate that high neutralizers have levels of the 20 most  
220 significant neutralization related DEPs which are generally similar regardless of disease  
221 severity.

222  
223 HSPA8 level predicts whether infection will elicit high levels of neutralizing antibodies

224  
225 We investigated whether we could predict strong neutralizing antibody responses based on  
226 the DEPs significantly associated with neutralization level. Participants were split into training  
227 (60%, n=42) and test (40%, n=29) groups. Significantly regulated proteins were determined  
228 by the same FDR and fold-change cut-off as used in the full set analysis (FDR<0.05, fold  
229 change $\geq$ 1.5), resulting in 12 significantly regulated proteins in the neutralization response in  
230 the training set (Figure S3). Repeated stepwise regression using bootstrapping was performed  
231 to rank the predictive power of each of the 12 proteins by iteratively subtracting or adding each  
232 of the proteins from/to the model. Stepwise regression was performed until the Akaike  
233 information criterion (AIC), a measure of the trade-off between goodness-of-fit and model  
234 complexity was optimized. The top three predictive proteins in order of significance were  
235 HSPA8, MLN, and FAP. They were combined in a multivariate logistic regression model  
236 (Figure 6A) and analyzed singly in univariate regression (Figure 6B-D).

237  
238 The combination of HSPA8, MLN, and FAP resulted in good discrimination between high  
239 neutralizers versus low neutralizers, showing an area under the curve (AUC) of 0.91 (Figure

240 6A). Using HSPA8 alone, the model could reasonably distinguish between low and high  
241 neutralization outcomes in the test group (AUC=0.86,  $p=0.0018$ , Figure 6B). The predictive  
242 power of FAP (AUC=0.84) and MLN (AUC=0.79) was slightly lower (Figure 6C-D).

243

#### 244 Similar severity related protein levels in high and low neutralizers with non-severe disease

245

246 Lastly, to test whether the similarity in disease severity between low and high neutralizers with  
247 non-severe disease was supported by the similarity in protein expression of severity-related  
248 proteins, we examined the top 20 significant by FDR proteins that were differentially expressed  
249 in the severe versus the non-severe groups. Included in this group was CAPN2, which  
250 increases the levels of the SARS-CoV-2 receptor ACE2<sup>51</sup>, and CD79A, a marker of B cell  
251 activation reported to be upregulated upon SARS-CoV-2 infection<sup>63</sup>.

252

253 We found that for 16 out of the top 20 DEPs examined, the expression level was not  
254 significantly different between the high and low neutralizers among the participants with non-  
255 severe disease (Figure 7). In addition, in all but two of the 16 proteins, there was a significant  
256 difference between both the high and low neutralizers with non-severe disease and the severe  
257 disease group. In 3 out of the remaining 4 DEPs which did not follow this pattern (furin,  
258 ANTXR2, and DNase1L2), the non-severe high neutralizers had intermediate protein levels  
259 which fell between the non-severe low neutralizers and the severe disease group.  
260 Interestingly, these DEPs were also common to both the severity and neutralization responses  
261 (Figure 3A-B). The fourth DEP, olfactomedin 2 (OLFM2), a protein mostly expressed in  
262 neurons and found to regulate metabolism<sup>64</sup>, did not show a significant difference between the  
263 non-severe high neutralizers and the severe disease group (Figure 7). These results indicate  
264 that, for the majority of the top 20 DEPs by significance which distinguished severe from non-  
265 severe disease participants, levels were similar between non-severe participants, regardless  
266 of participant neutralization capacity.

267

## 268 **Discussion**

269

270 We investigated disease severity, proteomic profiles, and infection-elicited neutralizing  
271 antibody levels in a cohort of 71 South African people infected with SARS-CoV-2 during the  
272 first ancestral SARS-CoV-2 infection wave. We stratified our cohort into severe and non-  
273 severe disease based on whether participants required supplemental oxygen and separated  
274 participants into high neutralizers and low neutralizers at convalescence based on their  
275 plasma neutralization capacity of ancestral SARS-CoV-2. We found that high disease severity  
276 and comorbidities were significantly associated with high neutralization capacity. However,  
277 there were participants with non-severe disease who had had similarly high neutralizing  
278 antibody levels to those with severe disease. These non-severe high neutralizers showed  
279 similar differentially expressed neutralization response protein levels to high neutralizers with  
280 severe disease. Meanwhile, their levels of differentially expressed proteins involved in disease  
281 severity were similar to participants with non-severe disease.

282

283 The enriched pathways we observed in high versus low neutralizers were generally associated  
284 with viral replication or the immune response. These included the interferon- $\alpha$  (IFN- $\alpha$ )  
285 response, a key part of the innate immune response to viral infections, with rapid production  
286 of IFN- $\alpha$  triggering antiviral and pro-inflammatory effects<sup>65</sup>; PI3k/Akt/mTOR signaling, which is  
287 is a mediator of cell cycle progression and cell survival<sup>66</sup>, with activation increasing viral  
288 replication<sup>67-69</sup>; Oxidative phosphorylation (OXPHOS), the process by which mitochondria  
289 generate ATP, with SARS-CoV-2 infection has been reported to promote OXPHOS and  
290 increases ATP production<sup>70</sup>; the mTORC1 pathway, a metabolic regulator of cell growth<sup>71</sup>, with

291 mTORC1 inhibitors shown to reduce SARS-CoV-2 replication<sup>72</sup>; hedgehog signaling, involved  
292 in development, cell proliferation, survival, and immune regulation, and modulated by multiple  
293 viruses<sup>73</sup>; fatty acid metabolism, the pathway in common between the neutralization response  
294 and disease severity, essential for the replication of enveloped viruses<sup>74-76</sup>. The other enriched  
295 pathways in the neutralization response may be associated with higher disease severity,  
296 although they do not come up as enriched pathways in the severe versus non-severe disease  
297 analysis: adipogenesis, associated with obesity, a known risk factor for severe Covid-19<sup>77-80</sup>,  
298 and upregulation of xenobiotic metabolism, which may indicate the presence of  
299 pharmacological interventions<sup>81</sup>.

300  
301 Like with the neutralization response, the enriched pathways in severe versus non-severe  
302 disease show links to SARS-CoV-2 replication. However, some make sense as consequences  
303 of severe disease independently of such replication. Thus, the upregulated pathway of  
304 glycolysis increases the replication of SARS-CoV-2 and other viruses<sup>82-84</sup>. However, hypoxia,  
305 which may have been present in participants with respiratory distress who required  
306 supplemental oxygen, also results in a metabolic switch from mitochondrial respiration to  
307 increased glycolysis<sup>85</sup>. The unfolded protein response may be upregulated because of the  
308 increased production of improperly folded proteins due to ER stress during SARS-CoV-2  
309 cellular infection<sup>86</sup>. Interestingly, ER stress and misfolded proteins have also been linked to  
310 autoimmune disease<sup>87</sup>, which has been reported to be elevated post-Covid-19<sup>88</sup>. Upregulation  
311 of proteins involved in the UV response may be because SARS-CoV-2 induces cell cycle  
312 arrest to gain cellular resources<sup>89</sup>. Decreased spermatogenesis, on the other hand, has been  
313 previously shown to be a consequence of severe Covid-19 leading to death<sup>91</sup>.

314  
315 For the neutralization response, differentially expressed proteins were measured at an earlier  
316 point in time than the neutralizing antibody response is thought to develop<sup>92</sup>. Therefore, they  
317 may be predictive. We found that three proteins, HSPA8, MLN, and FAP, could predict who  
318 will be high neutralizers. The best single protein predictor was HSPA8. This protein has  
319 multiple roles in cellular homeostasis, including a key role in the uncoating of endocytosed  
320 clathrin vesicles<sup>93</sup>. Interestingly, clathrin mediated endocytosis is a major cellular infection  
321 pathway for SARS-CoV-2<sup>94</sup> and facilitation of this process by HSPA8 may increase viral  
322 replication. In addition, HSPA8 has an important role in antigen presentation on MHC class II  
323 molecules<sup>44,46</sup>, a necessary step in the CD4 helper T cell - B cell interactions which are  
324 responsible for the production of effective neutralizing antibodies<sup>95</sup>.

325  
326 There was minor overlap between differentially expressed proteins and pathways involved in  
327 the neutralization response and the disease severity response. The minor overlap argues  
328 against the direct dependence of neutralizing antibody levels on disease severity and supports  
329 the proposition that a common factor such as high or prolonged viral replication results in both  
330 higher infection-elicited neutralization capacity and higher disease severity. However, a  
331 limitation to this conclusion is that, because of small group sizes, some differentially expressed  
332 proteins did not reach statistical significance in the disease severity response. For example,  
333 coagulation factor VWF was significantly higher in high neutralizers (FDR = 0.0001) but  
334 narrowly missed statistical significance in disease severity (FDR = 0.055). VWF was  
335 previously reported to be upregulated in high disease severity<sup>96</sup>. A second limitation is that our  
336 single measure, the requirement for supplemental oxygen, does not capture the range of more  
337 versus less severe disease, and therefore disease severity for some participants is  
338 misclassified. Nevertheless, while supplemental oxygen is not a perfect measure, most people  
339 with severe disease have respiratory failure, although they may die from multiorgan failure or  
340 other reasons<sup>97,98</sup>. The presence of non-severe high neutralizers, who have similar

341 neutralization response related protein profiles to severe high neutralizers, may mean that  
342 high disease severity is not essential to elicit a robust neutralizing antibody response.

343

## 344 **Methods**

### 345 Informed consent and ethical statement

346 This was an observational study with longitudinal sample collection. The nasopharyngeal  
347 swab used to isolate ancestral SARS-CoV-2 as well as all blood samples were obtained after  
348 written informed consent from adults with PCR-confirmed SARS-CoV-2 infection enrolled in a  
349 prospective cohort of SARS-CoV-2 infected individuals at the Africa Health Research Institute.  
350 The study protocol was approved by the Biomedical Research Ethics Committee at the  
351 University of KwaZulu-Natal (reference BREC/00001275/2020). Participants were reimbursed  
352 for each visit based on time, inconvenience and expenses as approved in the protocol.

### 353 Clinical laboratory testing

354 CD4 T cell count and HIV viral load quantification were performed from a 4mL EDTA tube of  
355 blood at an accredited diagnostic laboratory (Ampath for CD4 and Molecular Diagnostic  
356 Services for HIV viral load, both based in Durban, South Africa).

### 357 Cells

358 The VeroE6 cells expressing TMPRSS2 and ACE2 (Vero E6-TMPRSS2), originally BEI  
359 Resources, NR-54970, were used for virus expansion and live virus neutralization assays. The  
360 cell line was propagated in growth medium consisting of Dulbecco's Modified Eagle Medium  
361 (DMEM, Gibco 41965-039) with 10% fetal bovine serum (Hyclone, SV30160.03) containing  
362 10mM of hydroxyethylpiperazine ethanesulfonic acid (HEPES, Lonza, 17-737E), 1mM sodium  
363 pyruvate (Gibco, 11360-039), 2mM L-glutamine (Lonza BE17-605E) and 0.1mM nonessential  
364 amino acids (Lonza 13-114E).

### 365 Live virus neutralization assay (focus reduction neutralization assay)

366 For all neutralization assays, viral input was 100 focus forming units per well of a 96-well plate.  
367 VeroE6-TMPRSS2 cells were plated in a 96-well plate (Corning) at 30,000 cells per well 1 day  
368 pre-infection. Plasma was separated from EDTA-anticoagulated blood by centrifugation at 500  
369 × g for 10 min and stored at -80 °C. Aliquots of plasma samples were heat-inactivated at 56 °C  
370 for 30 minutes and clarified by centrifugation at 10,000 × g for 5 minutes. Virus stocks were  
371 added to serially diluted plasma in a 96-well plate (Corning) and antibody-virus mixtures were  
372 incubated for 1 h at 37 °C, 5% CO<sub>2</sub>. Cells were infected with 100 µL of the virus-antibody  
373 mixtures for 1 h, then 100 µL of a 1X RPMI 1640 (Sigma-Aldrich, R6504), 1.5%  
374 carboxymethylcellulose (Sigma-Aldrich, C4888) overlay was added without removing the  
375 inoculum. Cells were fixed 20 h post-infection using 4% PFA (Sigma-Aldrich, P6148) for 20  
376 min. Foci were stained with a rabbit anti-spike monoclonal antibody (BS-R2B12, GenScript  
377 A02058) at 0.5 µg/mL in a permeabilization buffer containing 0.1% saponin (Sigma-Aldrich,  
378 S7900), 0.1% BSA (Biowest, P6154) and 0.05% Tween-20 (Sigma-Aldrich, P9416) in PBS for  
379 2 h at room temperature with shaking, then washed with wash buffer containing 0.05% Tween-  
380 20 in PBS. Secondary goat anti-rabbit HRP conjugated antibody (Abcam ab205718) was  
381 added at 1 µg/mL and incubated for 2 h at room temperature with shaking. TrueBlue  
382 peroxidase substrate (SeraCare 5510-0030) was then added at 50 µL per well and incubated  
383 for 20 min at room temperature. Plates were imaged in an ImmunoSpot Ultra-V S6-02-6140  
384 Analyzer ELISPOT instrument with BioSpot Professional built-in image analysis (C.T.L).

### 385 Statistics and fitting



386 All statistics were performed in GraphPad Prism version 9.4.1. All fitting to determine FRNT<sub>50</sub>  
387 and linear regression was performed using custom code in MATLAB v.2019b (FRNT<sub>50</sub>) or the  
388 fit lm function for linear regression, which was also used to determine goodness-of-fit (R<sup>2</sup>) as  
389 well as p-value by F-test of the linear model. Limits of quantification were between 1:25 (most  
390 concentrated plasma used and 1:3200 (most dilute plasma used)

391 Neutralization data were fit to:

$$392 \quad Tx = 1 / (1 + (D / ID_{50})). \quad (1)$$

393 Here Tx is the number of foci at plasma dilution D normalized to the number of foci in the  
394 absence of plasma on the same plate. ID<sub>50</sub> is the plasma dilution, giving 50% neutralization.  
395 FRNT<sub>50</sub> = 1/ID<sub>50</sub>. Values of FRNT<sub>50</sub> < 1 are set to 1 (undiluted), the lowest measurable value.  
396 We note that FRNT<sub>50</sub> < 25 or FRNT<sub>50</sub> > 3200 fell outside of the dilution series used and were  
397 extrapolated from the fit.

#### 398 Plasma proteomic profiling

399 Proteomic analysis of the plasma samples was performed by SomaLogic, Inc. (Boulder, CO,  
400 USA) using the SomaScan v4.0 platform<sup>99</sup>. The SomaScan measures were reported as  
401 relative fluorescence units (RFU) in a summary ADAT file. These data were then merged with  
402 our metadata. Quantile normalization and log transformation were performed on all RFU-  
403 reported data to ensure comparability and normalization across samples.

#### 404 Differential protein analysis

405 The proteome changes attributable to both neutralization capacity and disease severity were  
406 derived from comparisons between individuals with high versus low neutralization capacity  
407 and severe versus non-severe outcomes, respectively. Protein data were log-transformed  
408 before testing the difference in means between comparison groups using the Student's t-test.  
409 P-values were corrected to control for the false discovery rate (FDR)<sup>100</sup>. The absolute fold  
410 change was rounded up to one decimal place (i.e, fold change values between 1.4 and 1.5  
411 were rounded to 1.5). Proteins with an adjusted p-value < 0.05 and absolute fold change ≥ 1.5  
412 were considered differentially expressed. These differentially expressed proteins were then  
413 visualized using a volcano plot in the R Project for statistical computing and graphical  
414 representation.

#### 415 Gene set enrichment analysis

416 Gene Set Enrichment Analysis (GSEA) was performed using the Broad Institute GSEA  
417 software version 4.3.3<sup>58,101</sup>, the MSigDB Hallmark gene sets (v2023.2), and the UniProt  
418 Human Collection chip platform. The GSEA software was downloaded from [https://www.gsea-](https://www.gsea-msigdb.org/gsea/downloads.jsp)  
419 [msigdb.org/gsea/downloads.jsp](https://www.gsea-msigdb.org/gsea/downloads.jsp), and GSEA was performed using default parameter settings  
420 except for Number of permutations = 10,000; Permutation type = gene\_set; 10 ≤ gene set size  
421 ≤ 500.

422

#### 423 Analysis of top variable proteins in the neutralization and severity responses

424 The top 20 variable proteins from the differential protein analysis of the neutralization response  
425 were selected based on FDR value. The proteins were standardized using Z-score  
426 normalization, where the mean level of a given protein is subtracted from each value of that  
427 protein, and the difference is divided by the protein's standard deviation. Pairwise differences  
428 in median protein levels between high neutralizers with severe disease, high neutralizers with  
429 non-severe disease, and low neutralizers (severe and non-severe) were assessed using  
430 Mann-Whitney U tests, with p-values adjusted for multiple comparisons using the Benjamini-

431 Hochberg method. Adjusted p-values < 0.05 were marked as significant. Outliers (absolute Z-  
432 score > 3) were included in the analysis but excluded from the plot for clarity of the  
433 visualization. The same analysis was carried out on the top 20 variable proteins in the severity  
434 response, except pairwise differences assessed were between severe disease (high and low  
435 neutralizers), non-severe high neutralizers, and non-severe low neutralizers.

#### 436 Logistic regression prediction model of neutralization outcome

437 Participants were split into training (60%, n=42) and testing (40%, n=29) sets. To identify a  
438 subset of proteins with the most potential predictive power of neutralization outcome, the  
439 training data were subjected to differential protein analysis as described above. This yielded  
440 12 significantly differentially expressed proteins (DEPs) between high and low neutralizers in  
441 the training data. The protein data in the training and testing sets were log-transformed and  
442 scaled by subtracting the mean and dividing by the standard deviation, with the mean and  
443 standard deviation of the training data used for both the training and testing sets. Using  
444 bootstrapping (1000 iterations with 100 participant values drawn with replacement per  
445 iteration), the neutralization response was iteratively modeled against the 12 DEPs and  
446 subjected to forward and backward stepwise regression, selecting the most significant  
447 predictors in a regression model by adding (forward) or subtracting (backward) predictors in a  
448 stepwise manner, optimizing for Akaike's information criterion (AIC). With each bootstrap  
449 iteration, the proteins selected by stepwise regression were added to a running tally, which  
450 served to rank the predictive power of the 12 DEPs upon completion of the bootstrapping.  
451 Neutralization response was fitted against the top three ranked proteins, MLN, FAP, and  
452 HSPA8, in a binomial logistic regression model, which was trained using the training data. The  
453 performance of this multivariate model and the constituent univariate models was assessed  
454 using the testing data of ROC curves, and AUC statistics were generated using the R pROC  
455 package.

#### 456 **Data availability**

457 The ancestral SARS-CoV-2 isolate used in this study for the neutralization assays has been  
458 deposited in GISAID and GenBank with accession numbers EPI\_ISL\_602626.1 (GISAID),  
459 OP090658 (GenBank). It is available upon reasonable request. All R-scripts used in the  
460 analysis have been deposited to GitHub (<https://github.com/Afrah-Khairallah/Omics->).

#### 461 **Author contributions**

462 A.S., A.K., and K.K. conceived the study and designed the study and experiments. Z.J., K.R.  
463 Y.G., B.I.G, F.K., Y.M., and K.K identified and provided samples and performed the  
464 neutralization experiments. T.N. provided resources. A.P., A.K., and A.S., and M.B. analyzed  
465 the data. A.S., A.P., and A.K. prepared the manuscript with input from all authors.

#### 466 **Acknowledgements**

467 We thank Clare Paterson and the team at SomaLogic for performing the proteomics and for  
468 helpful comments on the manuscript.

#### 469 **Funding**

470 This study was supported by the Bill and Melinda Gates award INV-018944 (AS) and the Bill  
471 and Melinda Gates Global Health Discovery Collaboratory.

472

## 473 References

474

- 475 1 Goldblatt, D., Alter, G., Crotty, S. & Plotkin, S. A. Correlates of protection against SARS-  
476 CoV-2 infection and COVID-19 disease. *Immunol Rev* **310**, 6-26 (2022). PMC9348242.  
477 10.1111/imr.13091
- 478
- 479 2 Pulliam, J. R. C., van Schalkwyk, C., Govender, N., von Gottberg, A., Cohen, C., Groome,  
480 M. J., Dushoff, J., Mlisana, K. & Moultrie, H. Increased risk of SARS-CoV-2 reinfection  
481 associated with emergence of Omicron in South Africa. *Science* **376**, eabn4947 (2022).  
482 PMC8995029. 10.1126/science.abn4947
- 483
- 484 3 Barnes, C. O., Jette, C. A., Abernathy, M. E., Dam, K. A., Esswein, S. R., Gristick, H. B.,  
485 Malyutin, A. G., Sharaf, N. G., Huey-Tubman, K. E., Lee, Y. E., Robbiani, D. F.,  
486 Nussenzweig, M. C., West, A. P., Jr. & Bjorkman, P. J. SARS-CoV-2 neutralizing antibody  
487 structures inform therapeutic strategies. *Nature* **588**, 682-687 (2020). PMC8092461.  
488 10.1038/s41586-020-2852-1
- 489
- 490 4 Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A.,  
491 Subbarao, K., Kent, S. J., Triccas, J. A. & Davenport, M. P. Neutralizing antibody levels are  
492 highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat*  
493 *Med* **27**, 1205-1211 (2021). 10.1038/s41591-021-01377-8
- 494
- 495 5 Cromer, D., Steain, M., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Kent, S. J.,  
496 Triccas, J. A., Khoury, D. S. & Davenport, M. P. Neutralising antibody titres as predictors  
497 of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis.  
498 *The Lancet Microbe* **3**, e52-e61 (2022).
- 499 6 Earle, K. A., Ambrosino, D. M., Fiore-Gartland, A., Goldblatt, D., Gilbert, P. B., Siber, G.  
500 R., Dull, P. & Plotkin, S. A. Evidence for antibody as a protective correlate for COVID-19  
501 vaccines. *Vaccine* **39**, 4423-4428 (2021). PMC8142841. 10.1016/j.vaccine.2021.05.063
- 502
- 503 7 Cromer, D., Steain, M., Reynaldi, A., Schlub, T. E., Khan, S. R., Sasson, S. C., Kent, S. J.,  
504 Khoury, D. S. & Davenport, M. P. Predicting vaccine effectiveness against severe COVID-  
505 19 over time and against variants: a meta-analysis. *Nat Commun* **14**, 1633 (2023).  
506 PMC10036966. 10.1038/s41467-023-37176-7
- 507
- 508 8 Garcia-Beltran, W. F., Lam, E. C., Astudillo, M. G., Yang, D., Miller, T. E., Feldman, J.,  
509 Hauser, B. M., Caradonna, T. M., Clayton, K. L., Nitido, A. D., Murali, M. R., Alter, G.,  
510 Charles, R. C., Dighe, A., Branda, J. A., Lennerz, J. K., Lingwood, D., Schmidt, A. G.,  
511 lafrate, A. J. & Balazs, A. B. COVID-19-neutralizing antibodies predict disease severity  
512 and survival. *Cell* **184**, 476-488.e411 (2021). PMC7837114. 10.1016/j.cell.2020.12.015
- 513
- 514 9 Lucas, C., Klein, J., Sundaram, M. E., Liu, F., Wong, P., Silva, J., Mao, T., Oh, J. E.,  
515 Mohanty, S., Huang, J., Tokuyama, M., Lu, P., Venkataraman, A., Park, A., Israelow, B.,  
516 Vogels, C. B. F., Muenker, M. C., Chang, C. H., Casanovas-Massana, A., Moore, A. J., Zell,  
517 J., Fournier, J. B., Obaid, A., Robertson, A. J., Lu-Culligan, A., Zhao, A., Nelson, A., Brito,  
518 A., Nunez, A., Martin, A., Watkins, A. E., Geng, B., Chun, C. J., Kalinich, C. C., Harden, C.

- 519 A., Todeasa, C., Jensen, C., Dorgay, C. E., Kim, D., McDonald, D., Shepard, D.,  
520 Courchaine, E., White, E. B., Song, E., Silva, E., Kudo, E., Deluliis, G., Rahming, H., Park,  
521 H.-J., Matos, I., Ott, I., Nouws, J., Valdez, J., Fauver, J., Lim, J., Rose, K.-A., Anastasio, K.,  
522 Brower, K., Glick, L., Sharma, L., Sewanan, L., Knaggs, L., Minasyan, M., Batsu, M.,  
523 Petrone, M., Kuang, M., Nakahata, M., Linehan, M., Askenase, M. H., Simonov, M.,  
524 Smolgovsky, M., Balkcom, N. C., Sonnert, N., Naushad, N., Vijayakumar, P., Martinello,  
525 R., Datta, R., Handoko, R., Bermejo, S., Prophet, S., Bickerton, S., Velazquez, S., Alpert,  
526 T., Rice, T., Khoury-Hanold, W., Peng, X., Yang, Y., Cao, Y., Strong, Y., Lin, Z., Wyllie, A. L.,  
527 Campbell, M., Lee, A. I., Chun, H. J., Grubaugh, N. D., Schulz, W. L., Farhadian, S., Dela  
528 Cruz, C., Ring, A. M., Shaw, A. C., Wisnewski, A. V., Yildirim, I., Ko, A. I., Omer, S. B.,  
529 Iwasaki, A. & Yale, I. R. T. Delayed production of neutralizing antibodies correlates with  
530 fatal COVID-19. *Nature Medicine* **27**, 1178-1186 (2021). 10.1038/s41591-021-01355-0
- 531  
532 10 Chen, X., Pan, Z., Yue, S., Yu, F., Zhang, J., Yang, Y., Li, R., Liu, B., Yang, X., Gao, L., Li, Z.,  
533 Lin, Y., Huang, Q., Xu, L., Tang, J., Hu, L., Zhao, J., Liu, P., Zhang, G., Chen, Y., Deng, K. &  
534 Ye, L. Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in  
535 COVID-19. *Signal Transduction and Targeted Therapy* **5**, 180 (2020). 10.1038/s41392-  
536 020-00301-9
- 537  
538 11 Trinité, B., Tarrés-Freixas, F., Rodon, J., Pradenas, E., Urrea, V., Marfil, S., Rodríguez de la  
539 Concepción, M. L., Ávila-Nieto, C., Aguilar-Gurrieri, C., Barajas, A., Ortiz, R., Paredes, R.,  
540 Mateu, L., Valencia, A., Guallar, V., Ruiz, L., Grau, E., Massanella, M., Puig, J., Chamorro,  
541 A., Izquierdo-Useros, N., Segalés, J., Clotet, B., Carrillo, J., Vergara-Alert, J. & Blanco, J.  
542 SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with  
543 disease severity. *Scientific Reports* **11**, 2608 (2021). 10.1038/s41598-021-81862-9
- 544  
545 12 Lau, E. H. Y., Tsang, O. T. Y., Hui, D. S. C., Kwan, M. Y. W., Chan, W.-h., Chiu, S. S., Ko, R.  
546 L. W., Chan, K. H., Cheng, S. M. S., Perera, R. A. P. M., Cowling, B. J., Poon, L. L. M. &  
547 Peiris, M. Neutralizing antibody titres in SARS-CoV-2 infections. *Nature Communications*  
548 **12**, 63 (2021). 10.1038/s41467-020-20247-4
- 549  
550 13 Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O.,  
551 O'Byrne, A., Kouphou, N., Galao, R. P., Betancor, G., Wilson, H. D., Signell, A. W.,  
552 Winstone, H., Kerridge, C., Huettner, I., Jimenez-Guardeño, J. M., Lista, M. J., Temperton,  
553 N., Snell, L. B., Bisnauthsing, K., Moore, A., Green, A., Martinez, L., Stokes, B., Honey, J.,  
554 Izquierdo-Barras, A., Arbane, G., Patel, A., Tan, M. K. I., O'Connell, L., O'Hara, G.,  
555 MacMahon, E., Douthwaite, S., Nebbia, G., Batra, R., Martinez-Nunez, R., Shankar-Hari,  
556 M., Edgeworth, J. D., Neil, S. J. D., Malim, M. H. & Doores, K. J. Longitudinal observation  
557 and decline of neutralizing antibody responses in the three months following SARS-CoV-  
558 2 infection in humans. *Nature Microbiology* **5**, 1598-1607 (2020). 10.1038/s41564-020-  
559 00813-8
- 560  
561 14 Legros, V., Denolly, S., Vogrig, M., Boson, B., Siret, E., Rigaille, J., Pillet, S., Grattard, F.,  
562 Gonzalo, S., Verhoeven, P., Allatif, O., Berthelot, P., Pélissier, C., Thiery, G., Botelho-  
563 Nevers, E., Millet, G., Morel, J., Paul, S., Walzer, T., Cosset, F.-L., Bourlet, T. & Pozzetto, B.  
564 A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between  
565 neutralizing antibodies and COVID-19 severity. *Cellular & Molecular Immunology* **18**,  
566 318-327 (2021). 10.1038/s41423-020-00588-2

- 567  
568 15 Schlickeiser, S., Schwarz, T., Steiner, S., Wittke, K., Al Beshar, N., Meyer, O., Kalus, U.,  
569 Pruß, A., Kurth, F., Zoller, T., Witzentrath, M., Sander, L. E., Müller, M. A., Scheibenbogen,  
570 C., Volk, H. D., Drosten, C., Corman, V. M. & Hanitsch, L. G. Disease Severity, Fever, Age,  
571 and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses. *Front Immunol*  
572 **11**, 628971 (2020). PMC7878374. 10.3389/fimmu.2020.628971
- 573  
574 16 Xu, X., Nie, S., Wang, Y., Long, Q., Zhu, H., Zhang, X., Sun, J., Zeng, Q., Zhao, J., Liu, L., Li,  
575 L., Huang, A., Hou, J. & Hou, F. F. Dynamics of neutralizing antibody responses to SARS-  
576 CoV-2 in patients with COVID-19: an observational study. *Signal Transduction and*  
577 *Targeted Therapy* **6**, 197 (2021). 10.1038/s41392-021-00611-6
- 578  
579 17 Kim, Y., Bae, J.-Y., Kwon, K., Chang, H.-H., Lee, W. K., Park, H., Kim, J., Choi, I., Park, M.-  
580 S. & Kim, S.-W. Kinetics of neutralizing antibodies against SARS-CoV-2 infection  
581 according to sex, age, and disease severity. *Scientific Reports* **12**, 13491 (2022).  
582 10.1038/s41598-022-17605-1
- 583  
584 18 Boonyaratanakornkit, J., Morishima, C., Selke, S., Zamora, D., McGuffin, S., Shapiro, A.  
585 E., Campbell, V. L., McClurkan, C. L., Jing, L., Gross, R., Liang, J., Postnikova, E., Mazur,  
586 S., Lukin, V. V., Chaudhary, A., Das, M. K., Fink, S. L., Bryan, A., Greninger, A. L., Jerome,  
587 K. R., Holbrook, M. R., Gernsheimer, T. B., Wener, M. H., Wald, A. & Koelle, D. M. Clinical,  
588 laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2  
589 among COVID-19 convalescent plasma donor candidates. *J Clin Invest* **131** (2021).  
590 PMC7843229. 10.1172/jci144930
- 591  
592 19 Klein, S. L., Pekosz, A., Park, H. S., Ursin, R. L., Shapiro, J. R., Benner, S. E., Littlefield, K.,  
593 Kumar, S., Naik, H. M., Betenbaugh, M. J., Shrestha, R., Wu, A. A., Hughes, R. M.,  
594 Burgess, I., Caturegli, P., Laeyendecker, O., Quinn, T. C., Sullivan, D., Shoham, S., Redd,  
595 A. D., Bloch, E. M., Casadevall, A. & Tobian, A. A. Sex, age, and hospitalization drive  
596 antibody responses in a COVID-19 convalescent plasma donor population. *J Clin Invest*  
597 **130**, 6141-6150 (2020). PMC7598041. 10.1172/jci142004
- 598  
599 20 Sui, Z., Dai, X., Lu, Q., Zhang, Y., Huang, M., Li, S., Peng, T., Xie, J., Zhang, Y., Wu, C., Xia,  
600 J., Dong, L., Yang, J., Huang, W., Liu, S., Wang, Z., Li, K., Yang, Q., Zhou, X., Wu, Y., Liu,  
601 W., Fang, X. & Peng, K. Viral dynamics and antibody responses in people with  
602 asymptomatic SARS-CoV-2 infection. *Signal Transduction and Targeted Therapy* **6**, 181  
603 (2021). 10.1038/s41392-021-00596-2
- 604  
605 21 Long, Q. X., Tang, X. J., Shi, Q. L., Li, Q., Deng, H. J., Yuan, J., Hu, J. L., Xu, W., Zhang, Y.,  
606 Lv, F. J., Su, K., Zhang, F., Gong, J., Wu, B., Liu, X. M., Li, J. J., Qiu, J. F., Chen, J. & Huang,  
607 A. L. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections.  
608 *Nat Med* **26**, 1200-1204 (2020). 10.1038/s41591-020-0965-6
- 609  
610 22 Western Cape Department of Health in collaboration with the National Institute for  
611 Communicable Diseases, S. A. Risk Factors for Coronavirus Disease 2019 (COVID-19)  
612 Death in a Population Cohort Study from the Western Cape Province, South Africa. *Clin*  
613 *Infect Dis* **73**, e2005-e2015 (2021). PMC7499501. 10.1093/cid/ciaa1198

- 614  
615 23 Wang, Y., Zhang, L., Sang, L., Ye, F., Ruan, S., Zhong, B., Song, T., Alshukairi, A. N., Chen,  
616 R., Zhang, Z., Gan, M., Zhu, A., Huang, Y., Luo, L., Mok, C. K. P., Al Gethamy, M. M., Tan,  
617 H., Li, Z., Huang, X., Li, F., Sun, J., Zhang, Y., Wen, L., Li, Y., Chen, Z., Zhuang, Z., Zhuo, J.,  
618 Chen, C., Kuang, L., Wang, J., Lv, H., Jiang, Y., Li, M., Lin, Y., Deng, Y., Tang, L., Liang, J.,  
619 Huang, J., Perlman, S., Zhong, N., Zhao, J., Malik Peiris, J. S., Li, Y. & Zhao, J. Kinetics of  
620 viral load and antibody response in relation to COVID-19 severity. *J Clin Invest* **130**, 5235-  
621 5244 (2020). PMC7524490. 10.1172/jci138759
- 622  
623 24 Lamers, M. M. & Haagmans, B. L. SARS-CoV-2 pathogenesis. *Nat Rev Microbiol* **20**, 270-  
624 284 (2022). 10.1038/s41579-022-00713-0
- 625  
626 25 Varga, Z., Flammer, A. J., Steiger, P., Haberecker, M., Andermatt, R., Zinkernagel, A. S.,  
627 Mehra, M. R., Schuepbach, R. A., Ruschitzka, F. & Moch, H. Endothelial cell infection  
628 and endotheliitis in COVID-19. *Lancet* **395**, 1417-1418 (2020). PMC7172722.  
629 10.1016/s0140-6736(20)30937-5
- 630  
631 26 Karim, F., Gazy, I., Cele, S., Zungu, Y., Krause, R., Bernstein, M., Khan, K., Ganga, Y.,  
632 Rodel, H., Mthabela, N., Mazibuko, M., Muema, D., Ramjit, D., Ndung'u, T., Hanekom,  
633 W., Gosnell, B., Team, C.-K., Lessells, R. J., Wong, E. B., de Oliveira, T., Moosa, M. S.,  
634 Lustig, G., Leslie, A., Klooverpris, H. & Sigal, A. HIV status alters disease severity and  
635 immune cell responses in Beta variant SARS-CoV-2 infection wave. *Elife* **10** (2021).  
636 PMC8676326. 10.7554/eLife.67397
- 637  
638 27 Bekker, L. G., Garrett, N., Goga, A., Fairall, L., Reddy, T., Yende-Zuma, N., Kassanje, R.,  
639 Collie, S., Sanne, I., Boule, A., Seocharan, I., Engelbrecht, I., Davies, M. A., Champion,  
640 J., Chen, T., Bennett, S., Mamejta, S., Semanya, M., Moultrie, H., de Oliveira, T., Lessells,  
641 R. J., Cohen, C., Jassat, W., Groome, M., Von Gottberg, A., Le Roux, E., Khuto, K.,  
642 Barouch, D., Mahomed, H., Wolmarans, M., Rousseau, P., Bradshaw, D., Mulder, M.,  
643 Opie, J., Louw, V., Jacobson, B., Rowji, P., Peter, J. G., Takalani, A., Odhiambo, J., Mayat,  
644 F., Takuva, S., Corey, L. & Gray, G. E. Effectiveness of the Ad26.COV2.S vaccine in health-  
645 care workers in South Africa (the Sisonke study): results from a single-arm, open-label,  
646 phase 3B, implementation study. *Lancet* **399**, 1141-1153 (2022). PMC8930006.  
647 10.1016/s0140-6736(22)00007-1
- 648  
649 28 Rubio-Rivas, M., Mora-Luján, J. M., Formiga, F., Arévalo-Cañas, C., Lebrón Ramos, J. M.,  
650 Villalba García, M. V., Fonseca Aizpuru, E. M., Díez-Manglano, J., Arnalich Fernández, F.,  
651 Romero Cabrera, J. L., García García, G. M., Pesqueira Fontan, P. M., Vargas Núñez, J. A.,  
652 Freire Castro, S. J., Loureiro Amigo, J., Pascual Pérez, M. L. R., Alcalá Pedrajas, J. N.,  
653 Encinas-Sánchez, D., Mella Pérez, C., Ena, J., Gracia Gutiérrez, A., Esteban Giner, M. J.,  
654 Varona, J. F., Millán Núñez-Cortés, J. & Casas-Rojo, J. M. WHO Ordinal Scale and  
655 Inflammation Risk Categories in COVID-19. Comparative Study of the Severity Scales. *J*  
656 *Gen Intern Med* **37**, 1980-1987 (2022). PMC8992782. 10.1007/s11606-022-07511-7
- 657  
658 29 Cele, S., Karim, F., Lustig, G., San, J. E., Hermanus, T., Tegally, H., Snyman, J., Moyo-  
659 Gwete, T., Wilkinson, E., Bernstein, M., Khan, K., Hwa, S. H., Tilles, S. W., Singh, L.,  
660 Giandhari, J., Mthabela, N., Mazibuko, M., Ganga, Y., Gosnell, B. I., Karim, S. S. A.,  
661 Hanekom, W., Van Voorhis, W. C., Ndung'u, T., Team, C.-K., Lessells, R. J., Moore, P. L.,

- 662 Moosa, M. S., de Oliveira, T. & Sigal, A. SARS-CoV-2 prolonged infection during advanced  
663 HIV disease evolves extensive immune escape. *Cell Host Microbe* **30**, 154-162 e155  
664 (2022). PMC8758318. 10.1016/j.chom.2022.01.005
- 665
- 666 30 Karim, F., Moosa, M. Y., Gosnell, B., Sandile, C., Giandhari, J., Pillay, S., Tegally, H.,  
667 Wilkinson, E., San, E. J. & Msomi, N. Persistent SARS-CoV-2 infection and intra-host  
668 evolution in association with advanced HIV infection. *medRxiv* (2021).
- 669 31 Karim, F., Riou, C., Bernstein, M., Jule, Z., Lustig, G., van Graan, S., Keeton, R. S., Upton,  
670 J.-L., Ganga, Y., Khan, K., Reedoy, K., Mazibuko, M., Govender, K., Thambu, K., Ngcobo,  
671 N., Venter, E., Makhado, Z., Hanekom, W., von Gottberg, A., Hoque, M., Karim, Q. A.,  
672 Abdool Karim, S. S., Manickchund, N., Magula, N., Gosnell, B. I., Lessells, R. J., Moore, P.  
673 L., Burgers, W. A., de Oliveira, T., Moosa, M.-Y. S. & Sigal, A. Clearance of persistent  
674 SARS-CoV-2 associates with increased neutralizing antibodies in advanced HIV disease  
675 post-ART initiation. *Nature Communications* **15**, 2360 (2024). 10.1038/s41467-024-  
676 46673-2
- 677
- 678 32 Cele, S., Gazy, I., Jackson, L., Hwa, S. H., Tegally, H., Lustig, G., Giandhari, J., Pillay, S.,  
679 Wilkinson, E., Naidoo, Y., Karim, F., Ganga, Y., Khan, K., Bernstein, M., Balazs, A. B.,  
680 Gosnell, B. I., Hanekom, W., Moosa, M. S., Network for Genomic Surveillance in South,  
681 A., Team, C.-K., Lessells, R. J., de Oliveira, T. & Sigal, A. Escape of SARS-CoV-2 501Y.V2  
682 from neutralization by convalescent plasma. *Nature* **593**, 142-146 (2021). PMC9867906.  
683 10.1038/s41586-021-03471-w
- 684
- 685 33 Cele, S., Jackson, L., Khoury, D. S., Khan, K., Moyo-Gwete, T., Tegally, H., San, J. E.,  
686 Cromer, D., Scheepers, C., Amoako, D. G., Karim, F., Bernstein, M., Lustig, G., Archary,  
687 D., Smith, M., Ganga, Y., Jule, Z., Reedoy, K., Hwa, S. H., Giandhari, J., Blackburn, J. M.,  
688 Gosnell, B. I., Abdool Karim, S. S., Hanekom, W., Ngs, S. A., Team, C.-K., von Gottberg,  
689 A., Bhiman, J. N., Lessells, R. J., Moosa, M. S., Davenport, M. P., de Oliveira, T., Moore, P.  
690 L. & Sigal, A. Omicron extensively but incompletely escapes Pfizer BNT162b2  
691 neutralization. *Nature* **602**, 654-656 (2022). PMC8866126. 10.1038/s41586-021-04387-1
- 692
- 693 34 Kharsany, A. B. M., Cawood, C., Khanyile, D., Lewis, L., Grobler, A., Puren, A., Govender,  
694 K., George, G., Beckett, S., Samsunder, N., Madurai, S., Toledo, C., Chipeta, Z.,  
695 Glenshaw, M., Hersey, S. & Abdool Karim, Q. Community-based HIV prevalence in  
696 KwaZulu-Natal, South Africa: results of a cross-sectional household survey. *Lancet HIV*  
697 **5**, e427-e437 (2018). PMC7498647. 10.1016/S2352-3018(18)30104-8
- 698
- 699 35 Shouman, S., El-Kholy, N., Hussien, A. E., El-Derby, A. M., Magdy, S., Abou-Shanab, A.  
700 M., Elmehrath, A. O., Abdelwaly, A., Helal, M. & El-Badri, N. SARS-CoV-2-associated  
701 lymphopenia: possible mechanisms and the role of CD147. *Cell Communication and*  
702 *Signaling* **22**, 349 (2024). 10.1186/s12964-024-01718-3
- 703
- 704 36 Zou, Z.-y., Ren, D., Chen, R.-l., Yu, B.-j., Liu, Y., Huang, J.-j., Yang, Z.-j., Zhou, Z.-p., Feng,  
705 Y.-w. & Wu, M. Persistent lymphopenia after diagnosis of COVID-19 predicts acute  
706 respiratory distress syndrome: A retrospective cohort study. *European Journal of*  
707 *Inflammation* **19**, 20587392211036825 (2021). 10.1177/20587392211036825
- 708

- 709 37 Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Tao, Y., Xie, C., Ma, K., Shang, K., Wang, W. &  
710 Tian, D.-S. Dysregulation of Immune Response in Patients With Coronavirus 2019  
711 (COVID-19) in Wuhan, China. *Clinical Infectious Diseases* **71**, 762-768 (2020).  
712 10.1093/cid/ciaa248
- 713
- 714 38 Li, X., Liu, C., Mao, Z., Xiao, M., Wang, L., Qi, S. & Zhou, F. Predictive values of neutrophil-  
715 to-lymphocyte ratio on disease severity and mortality in COVID-19 patients: a  
716 systematic review and meta-analysis. *Crit Care* **24**, 647 (2020). PMC7667659.  
717 10.1186/s13054-020-03374-8
- 718
- 719 39 Prebensen, C., Lefol, Y., Myhre, P. L., Lüders, T., Jonassen, C., Blomfeldt, A., Omland, T.,  
720 Nilsen, H. & Berdal, J.-E. Longitudinal whole blood transcriptomic analysis characterizes  
721 neutrophil activation and interferon signaling in moderate and severe COVID-19.  
722 *Scientific Reports* **13**, 10368 (2023). 10.1038/s41598-023-37606-y
- 723
- 724 40 Pietzner, M., Wheeler, E., Carrasco-Zanini, J., Raffler, J., Kerrison, N. D., Oerton, E.,  
725 Auyeung, V. P. W., Luan, J. a., Finan, C., Casas, J. P., Ostroff, R., Williams, S. A.,  
726 Kastenmüller, G., Ralser, M., Gamazon, E. R., Wareham, N. J., Hingorani, A. D. &  
727 Langenberg, C. Genetic architecture of host proteins involved in SARS-CoV-2 infection.  
728 *Nature Communications* **11**, 6397 (2020). 10.1038/s41467-020-19996-z
- 729
- 730 41 Yang, J., Chen, C., Chen, W., Huang, L., Fu, Z., Ye, K., Lv, L., Nong, Z., Zhou, X., Lu, W. &  
731 Zhong, M. Proteomics and metabolomics analyses of Covid-19 complications in  
732 patients with pulmonary fibrosis. *Scientific Reports* **11**, 14601 (2021). 10.1038/s41598-  
733 021-94256-8
- 734
- 735 42 Dunn, J., Ferluga, S., Sharma, V., Futschik, M., Hilton, D. A., Adams, C. L., Lasonder, E. &  
736 Hanemann, C. O. Proteomic analysis discovers the differential expression of novel  
737 proteins and phosphoproteins in meningioma including NEK9, HK2 and SET and  
738 deregulation of RNA metabolism. *EBioMedicine* **40**, 77-91 (2019). PMC6412084.  
739 10.1016/j.ebiom.2018.12.048
- 740
- 741 43 Liu, W., Xie, L., He, Y.-H., Wu, Z.-Y., Liu, L.-X., Bai, X.-F., Deng, D.-X., Xu, X.-E., Liao, L.-D.,  
742 Lin, W., Heng, J.-H., Xu, X., Peng, L., Huang, Q.-F., Li, C.-Y., Zhang, Z.-D., Wang, W.,  
743 Zhang, G.-R., Gao, X., Wang, S.-H., Li, C.-Q., Xu, L.-Y., Liu, W. & Li, E.-M. Large-scale and  
744 high-resolution mass spectrometry-based proteomics profiling defines molecular  
745 subtypes of esophageal cancer for therapeutic targeting. *Nature Communications* **12**,  
746 4961 (2021). 10.1038/s41467-021-25202-5
- 747
- 748 44 Stricher, F., Macri, C., Ruff, M. & Muller, S. HSPA8/HSC70 chaperone protein. *Autophagy*  
749 **9**, 1937-1954 (2013). 10.4161/auto.26448
- 750
- 751 45 Chappell, T. G., Welch, W. J., Schlossman, D. M., Palter, K. B., Schlesinger, M. J. &  
752 Rothman, J. E. Uncoating ATPase is a member of the 70 kilodalton family of stress  
753 proteins. *Cell* **45**, 3-13 (1986). 10.1016/0092-8674(86)90532-5
- 754



- 755 46 Panjwani, N., Akbari, O., Garcia, S., Brazil, M. & Stockinger, B. The HSC73 Molecular  
756 Chaperone: Involvement in MHC Class II Antigen Presentation. *The Journal of*  
757 *Immunology* **163**, 1936-1942 (1999). 10.4049/jimmunol.163.4.1936
- 758  
759 47 Navhaya, L. T., Blessing, D. M., Yamkela, M., Godlo, S. & Makhoba, X. H. A  
760 comprehensive review of the interaction between COVID-19 spike proteins with  
761 mammalian small and major heat shock proteins. *Biomolecular Concepts* **15** (2024).  
762 doi:10.1515/bmc-2022-0027
- 763  
764 48 Watanabe, K., Fuse, T., Asano, I., Tsukahara, F., Maru, Y., Nagata, K., Kitazato, K. &  
765 Kobayashi, N. Identification of Hsc70 as an influenza virus matrix protein (M1) binding  
766 factor involved in the virus life cycle. *FEBS Lett* **580**, 5785-5790 (2006).  
767 10.1016/j.febslet.2006.09.040
- 768  
769 49 Florin, L., Becker, K. A., Sapp, C., Lambert, C., Sirma, H., Müller, M., Streeck, R. E. &  
770 Sapp, M. Nuclear translocation of papillomavirus minor capsid protein L2 requires  
771 Hsc70. *J Virol* **78**, 5546-5553 (2004). PMC415841. 10.1128/jvi.78.11.5546-5553.2004
- 772  
773 50 Johnson, B. A., Xie, X., Bailey, A. L., Kalveram, B., Lokugamage, K. G., Muruato, A., Zou,  
774 J., Zhang, X., Juelich, T., Smith, J. K., Zhang, L., Bopp, N., Schindewolf, C., Vu, M.,  
775 Vanderheiden, A., Winkler, E. S., Swetnam, D., Plante, J. A., Aguilar, P., Plante, K. S.,  
776 Popov, V., Lee, B., Weaver, S. C., Suthar, M. S., Routh, A. L., Ren, P., Ku, Z., An, Z.,  
777 Debbink, K., Diamond, M. S., Shi, P. Y., Freiberg, A. N. & Menachery, V. D. Loss of furin  
778 cleavage site attenuates SARS-CoV-2 pathogenesis. *Nature* **591**, 293-299 (2021).  
779 PMC8175039. 10.1038/s41586-021-03237-4
- 780  
781 51 Zeng, Q., Antia, A., Casorla-Perez, L. A., Puray-Chavez, M., Kutluay, S. B., Ciorba, M. A. &  
782 Ding, S. Calpain-2 mediates SARS-CoV-2 entry via regulating ACE2 levels. *mbio* **15**,  
783 e02287-02223 (2024). doi:10.1128/mbio.02287-23
- 784  
785 52 Shiokawa, D., Matsushita, T., Kobayashi, T., Matsumoto, Y. & Tanuma, S.-i.  
786 Characterization of the human DNAS1L2 gene and the molecular mechanism for its  
787 transcriptional activation induced by inflammatory cytokines. *Genomics* **84**, 95-105  
788 (2004).
- 789 53 Anelli, T., Alessio, M., Mezghrani, A., Simmen, T., Talamo, F., Bachi, A. & Sitia, R. ERp44, a  
790 novel endoplasmic reticulum folding assistant of the thioredoxin family. *The EMBO*  
791 *Journal* **21**, 835-844 (2002). <https://doi.org/10.1093/emboj/21.4.835>
- 792  
793 54 Liu, P., Wang, X., Sun, Y., Zhao, H., Cheng, F., Wang, J., Yang, F., Hu, J., Zhang, H., Wang,  
794 C.-c. & Wang, L. SARS-CoV-2 ORF8 reshapes the ER through forming mixed disulfides  
795 with ER oxidoreductases. *Redox Biology* **54**, 102388 (2022).  
796 <https://doi.org/10.1016/j.redox.2022.102388>
- 797  
798 55 Sun, J. & Jacquez, P. Roles of Anthrax Toxin Receptor 2 in Anthrax Toxin Membrane  
799 Insertion and Pore Formation. *Toxins (Basel)* **8**, 34 (2016). PMC4773787.  
800 10.3390/toxins8020034

- 801  
802 56 Needham, B. E., Wlodek, M. E., Ciccotosto, G. D., Fam, B. C., Masters, C. L., Proietto, J.,  
803 Andrikopoulos, S. & Cappai, R. Identification of the Alzheimer's disease amyloid  
804 precursor protein (APP) and its homologue APLP2 as essential modulators of glucose  
805 and insulin homeostasis and growth. *J Pathol* **215**, 155-163 (2008). 10.1002/path.2343
- 806  
807 57 Chen, J., Chen, J., Lei, Z., Zhang, F., Zeng, L. H., Wu, X., Li, S. & Tan, J. Amyloid precursor  
808 protein facilitates SARS-CoV-2 virus entry into cells and enhances amyloid- $\beta$ -associated  
809 pathology in APP/PS1 mouse model of Alzheimer's disease. *Transl Psychiatry* **13**, 396  
810 (2023). PMC10725492. 10.1038/s41398-023-02692-z
- 811  
812 58 Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A.,  
813 Paulovich, A., Pomeroy, S. L., Golub, T. R. & Lander, E. S. Gene set enrichment analysis:  
814 a knowledge-based approach for interpreting genome-wide expression profiles.  
815 *Proceedings of the National Academy of Sciences* **102**, 15545-15550 (2005).
- 816 59 Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P. & Tamayo, P. The  
817 molecular signatures database hallmark gene set collection. *Cell systems* **1**, 417-425  
818 (2015).
- 819 60 Fitzgerald, A. A. & Weiner, L. M. The role of fibroblast activation protein in health and  
820 malignancy. *Cancer Metastasis Rev* **39**, 783-803 (2020). PMC7487063. 10.1007/s10555-  
821 020-09909-3
- 822  
823 61 Deloose, E., Verbeure, W., Depoortere, I. & Tack, J. Motilin: from gastric motility  
824 stimulation to hunger signalling. *Nature Reviews Endocrinology* **15**, 238-250 (2019).  
825 10.1038/s41574-019-0155-0
- 826  
827 62 Tsai, H. Y., Yang, Y. F., Wu, A. T., Yang, C. J., Liu, Y. P., Jan, Y. H., Lee, C. H., Hsiao, Y. W.,  
828 Yeh, C. T., Shen, C. N., Lu, P. J., Huang, M. S. & Hsiao, M. Endoplasmic reticulum  
829 ribosome-binding protein 1 (RRBP1) overexpression is frequently found in lung cancer  
830 patients and alleviates intracellular stress-induced apoptosis through the enhancement  
831 of GRP78. *Oncogene* **32**, 4921-4931 (2013). 10.1038/onc.2012.514
- 832  
833 63 McClain, M. T., Constantine, F. J., Henao, R., Liu, Y., Tsalik, E. L., Burke, T. W., Steinbrink,  
834 J. M., Petzold, E., Nicholson, B. P., Rolfe, R., Kraft, B. D., Kelly, M. S., Saban, D. R., Yu, C.,  
835 Shen, X., Ko, E. M., Sempowski, G. D., Denny, T. N., Ginsburg, G. S. & Woods, C. W.  
836 Dysregulated transcriptional responses to SARS-CoV-2 in the periphery. *Nature*  
837 *Communications* **12**, 1079 (2021). 10.1038/s41467-021-21289-y
- 838  
839 64 González-García, I., Freire-Agulleiro, Ó., Nakaya, N., Ortega, F. J., Garrido-Gil, P.,  
840 Liñares-Pose, L., Fernø, J., Labandeira-Garcia, J. L., Diéguez, C., Sultana, A., Tomarev, S.  
841 I., Fernández-Real, J. M. & López, M. Olfactomedin 2 deficiency protects against diet-  
842 induced obesity. *Metabolism* **129**, 155122 (2022).  
843 <https://doi.org/10.1016/j.metabol.2021.155122>
- 844  
845 65 Kim, Y.-M. & Shin, E.-C. Type I and III interferon responses in SARS-CoV-2 infection.  
846 *Experimental & Molecular Medicine* **53**, 750-760 (2021). 10.1038/s12276-021-00592-0
- 847

- 848 66 Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair,  
849 M. G., Makvandi, P., Geoerger, B., Kulke, M. H., Baird, R. D., Prabhu, J. S., Carbone, D.,  
850 Pecoraro, C., Teh, D. B. L., Sethi, G., Cavalieri, V., Lin, K. H., Javidi-Sharifi, N. R., Toska,  
851 E., Davids, M. S., Brown, J. R., Diana, P., Stebbing, J., Fruman, D. A. & Kumar, A. P.  
852 PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer.  
853 *Molecular Cancer* **22**, 138 (2023). 10.1186/s12943-023-01827-6
- 854  
855 67 Fattahi, S., Khalifehzadeh-Esfahani, Z., Mohammad-Rezaei, M., Mafi, S. & Jafarinia, M.  
856 PI3K/Akt/mTOR pathway: a potential target for anti-SARS-CoV-2 therapy. *Immunol Res*  
857 **70**, 269-275 (2022). PMC8808470. 10.1007/s12026-022-09268-x
- 858  
859 68 Basile, M. S., Cavalli, E., McCubrey, J., Hernández-Bello, J., Muñoz-Valle, J. F., Fagone, P.  
860 & Nicoletti, F. The PI3K/Akt/mTOR pathway: A potential pharmacological target in  
861 COVID-19. *Drug Discovery Today* **27**, 848-856 (2022).  
862 <https://doi.org/10.1016/j.drudis.2021.11.002>
- 863  
864 69 Abu-Eid, R. & Ward, F. J. Targeting the PI3K/Akt/mTOR pathway: A therapeutic strategy in  
865 COVID-19 patients. *Immunology Letters* **240**, 1-8 (2021).  
866 <https://doi.org/10.1016/j.imlet.2021.09.005>
- 867  
868 70 Shin, H. J., Lee, W., Ku, K. B., Yoon, G. Y., Moon, H.-W., Kim, C., Kim, M.-H., Yi, Y.-S., Jun,  
869 S., Kim, B.-T., Oh, J.-W., Siddiqui, A. & Kim, S.-J. SARS-CoV-2 aberrantly elevates  
870 mitochondrial bioenergetics to induce robust virus propagation. *Signal Transduction*  
871 *and Targeted Therapy* **9**, 125 (2024). 10.1038/s41392-024-01836-x
- 872  
873 71 Ben-Sahra, I. & Manning, B. D. mTORC1 signaling and the metabolic control of cell  
874 growth. *Current Opinion in Cell Biology* **45**, 72-82 (2017).  
875 <https://doi.org/10.1016/j.ceb.2017.02.012>
- 876  
877 72 Mullen, P. J., Garcia, G., Purkayastha, A., Matulionis, N., Schmid, E. W., Momcilovic, M.,  
878 Sen, C., Langerman, J., Ramaiah, A., Shackelford, D. B., Damoiseaux, R., French, S. W.,  
879 Plath, K., Gomperts, B. N., Arumugaswami, V. & Christofk, H. R. SARS-CoV-2 infection  
880 rewires host cell metabolism and is potentially susceptible to mTORC1 inhibition.  
881 *Nature Communications* **12**, 1876 (2021). 10.1038/s41467-021-22166-4
- 882  
883 73 Zhou, Y., Huang, J., Jin, B., He, S., Dang, Y., Zhao, T. & Jin, Z. The Emerging Role of  
884 Hedgehog Signaling in Viral Infections. *Front Microbiol* **13**, 870316 (2022). PMC9023792.  
885 10.3389/fmicb.2022.870316
- 886  
887 74 Abu-Farha, M., Thanaraj, T. A., Qaddoumi, M. G., Hashem, A., Abubaker, J. & Al-Mulla, F.  
888 The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target. *Int J Mol*  
889 *Sci* **21** (2020). PMC7278986. 10.3390/ijms21103544
- 890  
891 75 D'Avila, H., Lima, C. N. R., Rampinelli, P. G., Mateus, L. C. O., Sousa Silva, R. V. d.,  
892 Correa, J. R. & Almeida, P. E. d. Lipid Metabolism Modulation during SARS-CoV-2

- 893 Infection: A Spotlight on Extracellular Vesicles and Therapeutic Prospects. *International*  
894 *Journal of Molecular Sciences* **25**, 640 (2024).
- 895 76 Chu, J., Xing, C., Du, Y., Duan, T., Liu, S., Zhang, P., Cheng, C., Henley, J., Liu, X., Qian, C.,  
896 Yin, B., Wang, H. Y. & Wang, R.-F. Pharmacological inhibition of fatty acid synthesis  
897 blocks SARS-CoV-2 replication. *Nature Metabolism* **3**, 1466-1475 (2021).  
898 10.1038/s42255-021-00479-4
- 899
- 900 77 Petrilli, C. M., Jones, S. A., Yang, J., Rajagopalan, H., O'Donnell, L., Chernyak, Y., Tobin, K.  
901 A., Cerfolio, R. J., Francois, F. & Horwitz, L. I. Factors associated with hospital admission  
902 and critical illness among 5279 people with coronavirus disease 2019 in New York City:  
903 prospective cohort study. *Bmj* **369**, m1966 (2020). PMC7243801. 10.1136/bmj.m1966
- 904
- 905 78 Tartof, S. Y., Qian, L., Hong, V., Wei, R., Nadjafi, R. F., Fischer, H., Li, Z., Shaw, S. F.,  
906 Caparosa, S. L., Nau, C. L., Saxena, T., Rieg, G. K., Ackerson, B. K., Sharp, A. L.,  
907 Skarbinski, J., Naik, T. K. & Murali, S. B. Obesity and Mortality Among Patients Diagnosed  
908 With COVID-19: Results From an Integrated Health Care Organization. *Ann Intern Med*  
909 **173**, 773-781 (2020). PMC7429998. 10.7326/m20-3742
- 910
- 911 79 Moriconi, D., Masi, S., Rebelos, E., Viridis, A., Manca, M. L., De Marco, S., Taddei, S. &  
912 Nannipieri, M. Obesity prolongs the hospital stay in patients affected by COVID-19, and  
913 may impact on SARS-COV-2 shedding. *Obes Res Clin Pract* **14**, 205-209 (2020).  
914 PMC7269944. 10.1016/j.orcp.2020.05.009
- 915
- 916 80 Martínez-Colón, G. J., Ratnasiri, K., Chen, H., Jiang, S., Zanley, E., Rustagi, A., Verma, R.,  
917 Chen, H., Andrews, J. R., Mertz, K. D., Tzankov, A., Azagury, D., Boyd, J., Nolan, G. P.,  
918 Schürch, C. M., Matter, M. S., Blish, C. A. & McLaughlin, T. L. SARS-CoV-2 infection  
919 drives an inflammatory response in human adipose tissue through infection of  
920 adipocytes and macrophages. *Science Translational Medicine* **14**, eabm9151 (2022).  
921 doi:10.1126/scitranslmed.abm9151
- 922
- 923 81 Johnson, C. H., Patterson, A. D., Idle, J. R. & Gonzalez, F. J. Xenobiotic metabolomics:  
924 major impact on the metabolome. *Annu Rev Pharmacol Toxicol* **52**, 37-56 (2012).  
925 PMC6300990. 10.1146/annurev-pharmtox-010611-134748
- 926
- 927 82 Codo, A. C., Davanzo, G. G., Monteiro, L. B., de Souza, G. F., Muraro, S. P., Virgilio-da-  
928 Silva, J. V., Prodonoff, J. S., Carregari, V. C., de Biagi Junior, C. A. O., Crunfli, F., Jimenez  
929 Restrepo, J. L., Vendramini, P. H., Reis-de-Oliveira, G., Bispo Dos Santos, K., Toledo-  
930 Teixeira, D. A., Parise, P. L., Martini, M. C., Marques, R. E., Carmo, H. R., Borin, A.,  
931 Coimbra, L. D., Boldrini, V. O., Brunetti, N. S., Vieira, A. S., Mansour, E., Ulaf, R. G.,  
932 Bernardes, A. F., Nunes, T. A., Ribeiro, L. C., Palma, A. C., Agrela, M. V., Moretti, M. L.,  
933 Sposito, A. C., Pereira, F. B., Velloso, L. A., Vinolo, M. A. R., Damasio, A., Proença-  
934 Módena, J. L., Carvalho, R. F., Mori, M. A., Martins-de-Souza, D., Nakaya, H. I., Farias, A.  
935 S. & Moraes-Vieira, P. M. Elevated Glucose Levels Favor SARS-CoV-2 Infection and  
936 Monocyte Response through a HIF-1 $\alpha$ /Glycolysis-Dependent Axis. *Cell Metab* **32**, 437-  
937 446.e435 (2020). PMC7367032. 10.1016/j.cmet.2020.07.007
- 938

- 939 83 Sanchez, E. L. & Lagunoff, M. Viral activation of cellular metabolism. *Virology* **479-480**,  
940 609-618 (2015). PMC4424078. 10.1016/j.virol.2015.02.038
- 941
- 942 84 Chen, P., Wu, M., He, Y., Jiang, B. & He, M.-L. Metabolic alterations upon SARS-CoV-2  
943 infection and potential therapeutic targets against coronavirus infection. *Signal*  
944 *Transduction and Targeted Therapy* **8**, 237 (2023). 10.1038/s41392-023-01510-8
- 945
- 946 85 Kierans, S. J. & Taylor, C. T. Regulation of glycolysis by the hypoxia-inducible factor (HIF):  
947 implications for cellular physiology. *J Physiol* **599**, 23-37 (2021). 10.1113/jp280572
- 948
- 949 86 Keramidis, P., Pitou, M., Papachristou, E. & Choli-Papadopoulou, T. Insights into the  
950 Activation of Unfolded Protein Response Mechanism during Coronavirus Infection.  
951 *Current Issues in Molecular Biology* **46**, 4286-4308 (2024).
- 952 87 Barrera, M. J., Aguilera, S., Castro, I., González, S., Carvajal, P., Molina, C., Hermoso, M.  
953 A. & González, M. J. Endoplasmic reticulum stress in autoimmune diseases: Can altered  
954 protein quality control and/or unfolded protein response contribute to autoimmunity? A  
955 critical review on Sjögren's syndrome. *Autoimmun Rev* **17**, 796-808 (2018).  
956 10.1016/j.autrev.2018.02.009
- 957
- 958 88 Sharma, C. & Bayry, J. High risk of autoimmune diseases after COVID-19. *Nature*  
959 *Reviews Rheumatology* **19**, 399-400 (2023). 10.1038/s41584-023-00964-y
- 960
- 961 89 Sui, L., Li, L., Zhao, Y., Zhao, Y., Hao, P., Guo, X., Wang, W., Wang, G., Li, C. & Liu, Q. Host  
962 cell cycle checkpoint as antiviral target for SARS-CoV-2 revealed by integrative  
963 transcriptome and proteome analyses. *Signal Transduction and Targeted Therapy* **8**, 21  
964 (2023). 10.1038/s41392-022-01296-1
- 965
- 966 90 Wisdom, R., Johnson, R. S. & Moore, C. c-Jun regulates cell cycle progression and  
967 apoptosis by distinct mechanisms. *The EMBO Journal* **18**, 188-197 (1999).  
968 <https://doi.org/10.1093/emboj/18.1.188>
- 969
- 970 91 Li, H., Xiao, X., Zhang, J., Zafar, M. I., Wu, C., Long, Y., Lu, W., Pan, F., Meng, T., Zhao, K.,  
971 Zhou, L., Shen, S., Liu, L., Liu, Q. & Xiong, C. Impaired spermatogenesis in COVID-19  
972 patients. *EClinicalMedicine* **28**, 100604 (2020). PMC7584442.  
973 10.1016/j.eclinm.2020.100604
- 974
- 975 92 Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A.,  
976 Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., Hoelscher, M., Bleicker, T., Brünink, S.,  
977 Schneider, J., Ehmann, R., Zwirgmaier, K., Drosten, C. & Wendtner, C. Virological  
978 assessment of hospitalized patients with COVID-2019. *Nature* **581**, 465-469 (2020).  
979 10.1038/s41586-020-2196-x
- 980
- 981 93 Sousa, R. & Lafer, E. M. The role of molecular chaperones in clathrin mediated vesicular  
982 trafficking. *Front Mol Biosci* **2**, 26 (2015). PMC4436892. 10.3389/fmolb.2015.00026
- 983

- 984 94 Bayati, A., Kumar, R., Francis, V. & McPherson, P. S. SARS-CoV-2 infects cells after viral  
985 entry via clathrin-mediated endocytosis. *J Biol Chem* **296**, 100306 (2021). PMC7816624.  
986 10.1016/j.jbc.2021.100306
- 987
- 988 95 Lanzavecchia, A. Antigen-specific interaction between T and B cells. *Nature* **314**, 537-  
989 539 (1985).
- 990 96 van den Berg, J., Haslbauer, J. D., Stalder, A. K., Romanens, A., Mertz, K. D., Studt, J.-D.,  
991 Siegemund, M., Buser, A., Holbro, A. & Tzankov, A. Von Willebrand factor and the  
992 thrombophilia of severe COVID-19: in situ evidence from autopsies. *Research and*  
993 *Practice in Thrombosis and Haemostasis* **7**, 100182 (2023).  
994 <https://doi.org/10.1016/j.rpth.2023.100182>
- 995
- 996 97 Fitzek, A., Schädler, J., Dietz, E., Ron, A., Gerling, M., Kammal, A. L., Lohner, L., Falck, C.,  
997 Möbius, D., Goebels, H., Gerberding, A.-L., Schröder, A. S., Sperhake, J.-P., Klein, A.,  
998 Fröb, D., Mushumba, H., Wilmes, S., Anders, S., Kniep, I., Heinrich, F., Langenwalder, F.,  
999 Meißner, K., Lange, P., Zapf, A., Püschel, K., Heinemann, A., Glatzel, M., Matschke, J.,  
1000 Aepfelbacher, M., Lütgehetmann, M., Steurer, S., Thorns, C., Edler, C. & Ondruschka, B.  
1001 Prospective postmortem evaluation of 735 consecutive SARS-CoV-2-associated death  
1002 cases. *Scientific Reports* **11**, 19342 (2021). 10.1038/s41598-021-98499-3
- 1003
- 1004 98 Elezkurtaj, S., Greuel, S., Ihlow, J., Michaelis, E. G., Bischoff, P., Kunze, C. A., Sinn, B. V.,  
1005 Gerhold, M., Hauptmann, K., Ingold-Heppner, B., Miller, F., Herbst, H., Corman, V. M.,  
1006 Martin, H., Radbruch, H., Heppner, F. L. & Horst, D. Causes of death and comorbidities  
1007 in hospitalized patients with COVID-19. *Scientific Reports* **11**, 4263 (2021).  
1008 10.1038/s41598-021-82862-5
- 1009
- 1010 99 Kraemer, S., Vaught, J. D., Bock, C., Gold, L., Katilius, E., Keeney, T. R., Kim, N.,  
1011 Saccomano, N. A., Wilcox, S. K. & Zichi, D. From SOMAmer-based biomarker discovery  
1012 to diagnostic and clinical applications: a SOMAmer-based, streamlined multiplex  
1013 proteomic assay. *PloS one* **6**, e26332 (2011).
- 1014 100 Storey, J. D. A direct approach to false discovery rates. *Journal of the Royal Statistical*  
1015 *Society: Series B (Statistical Methodology)* **64**, 479-498 (2002).  
1016 <https://doi.org/10.1111/1467-9868.00346>
- 1017
- 1018 101 Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J.,  
1019 Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., Houstis, N., Daly, M. J.,  
1020 Patterson, N., Mesirov, J. P., Golub, T. R., Tamayo, P., Spiegelman, B., Lander, E. S.,  
1021 Hirschhorn, J. N., Altshuler, D. & Groop, L. C. PGC-1 $\alpha$ -responsive genes involved in  
1022 oxidative phosphorylation are coordinately downregulated in human diabetes. *Nature*  
1023 *Genetics* **34**, 267-273 (2003). 10.1038/ng1180
- 1024
- 1025
- 1026

1027 **Figure legends**

1028

1029 **Figure 1: Study design and timeline.** Study participants were enrolled in the first South  
1030 African SARS-CoV-2 infection wave between March and October 2020, where enrollment was  
1031 a median of 6 days post-diagnosis. At enrollment, disease severity was assessed by whether  
1032 a participant required supplemental oxygen. During this visit, a blood draw was performed,  
1033 and blood plasma used for proteomic analysis using SomaScan proteomics. At 28 days post-  
1034 enrollment, a second blood draw was performed, and blood plasma was used in a live virus  
1035 neutralization assay against ancestral SARS-CoV-2 to assess neutralization capacity.

1036

1037 **Figure 2: Neutralization capacity associates with disease severity but not HIV status.**  
1038 (A) Participants were divided into high and low neutralizers based on whether the participant's  
1039 plasma showed higher or lower neutralizing capacity relative to the median neutralization  
1040 FRNT<sub>50</sub> of all participants. For all plots, y-axis shows FRNT<sub>50</sub>, with bar and error bars  
1041 representing the geometric mean and geometric standard deviation of each group. The  
1042 horizontal dashed red line marks the limit of quantification (the inverse of the highest plasma  
1043 concentration used). (B) Participants in the high and low neutralization groups who required  
1044 supplemental oxygen (red points). Inset shows frequency of participants on supplemental  
1045 oxygen in each group (p=0.0046 by Fisher's exact test). (C) High and low neutralizers who  
1046 had a neutrophil to lymphocyte ratio (NLR) greater than 6. Inset: frequency of high NLR in  
1047 each group (p=0.011 by Fisher's exact test). (D) High and low neutralizers who had a  
1048 comorbidity of diabetes, hypertension, or both. Inset: frequency of comorbidities in each group  
1049 (p=0.00018 by Fisher's exact test). (E) High and low neutralizers who were male. Inset:  
1050 frequency of males in each group (p=0.042 by Fisher's exact test). (F) High and low  
1051 neutralizers who were people living with HIV (PLWH). Inset: frequency of PLWH in each group  
1052 (not significant by Fisher's exact test). (G) Univariate and (H) multivariate logistic regression  
1053 odds ratios for odds of having a high neutralization response.

1054

1055 **Figure 3: Differentially expressed proteins in neutralization and disease severity.**  
1056 Volcano plots show fold-change versus false discovery rate (FDR) values for each protein in  
1057 two comparisons: (A) High neutralizers compared to low neutralizers; (B) severe versus non-  
1058 severe disease. The x-axis represents the log fold-change between the mean protein level  
1059 values in the group of high versus low neutralizers or high versus low disease severity. Y-axis  
1060 is the  $-\log_{10}$  transformed FDR. The vertical lines indicate  $\pm 1.5$ -fold change and the horizontal  
1061 line FDR=0.05. Significantly differentially expressed proteins are labeled in red (upregulated),  
1062 blue (downregulated), and green (shared between responses). (C) Venn diagram showing the  
1063 number of differentially expressed proteins associated with neutralization capacity and  
1064 disease severity and common to both.

1065

1066 **Figure 4. Significantly regulated pathways for neutralization and disease severity.** Gene  
1067 Set Enrichment Analysis (GSEA) results for significantly up or downregulated pathways in  
1068 participants with high neutralization versus low capacity and those with severe versus non-  
1069 severe disease. The x-axis represents the Normalized Enrichment Score (NES). Each circle  
1070 represents a pathway, with the size of the circle corresponding to the  $-\log_{10}$ (FDR) value, with  
1071 larger circles indicating higher significance. Purple circles represent pathways enriched in the  
1072 high neutralization group and orange circles represent pathways enriched in the severe  
1073 disease group. One pathway (fatty acid metabolism) is shared between both groups.

1074

1075 **Figure 5: Top differentially expressed proteins in the neutralization response show**  
1076 **similar expression in high neutralizers regardless of disease severity.** Median Z-score  
1077 normalized protein levels of the top 20 differentially expressed proteins by FDR are shown for  
1078 the high neutralizers with severe disease, high neutralizers with non-severe disease, and low  
1079 neutralizers. Fourteen out of the 20 proteins (left) show no significant difference between the  
1080 high neutralizers with severe disease versus high neutralizers with non-severe disease. Six  
1081 proteins (right) show significantly higher levels in high neutralizers with severe disease relative  
1082 to high neutralizers with non-severe disease. However, the levels of these proteins in low  
1083 neutralizers are significantly lower still. P-values by the Kruskal-Wallis test with multiple  
1084 hypothesis correction between group values per protein.

1085

1086 **Figure 6: Predictive models classifying participants into high versus low neutralization**  
1087 **groups.** Shown are ROC curves for (A) multivariate (HSPA8+FAP+MLN), (B) HSPA8, (C) FAP,  
1088 and (D) MLN. Areas Under the Curve (AUC) were 0.91 (multivariate), 0.86 (HSPA8), 0.84  
1089 (FAP), and 0.79 (MLN). Dashed diagonal line represents the performance of a random  
1090 classifier with AUC=0.50.

1091

1092 **Figure 7: Top differentially expressed proteins in the disease severity response show**  
1093 **similar expression regardless of neutralization capacity.** Median Z-score normalized  
1094 protein of the top 20 differentially expressed proteins by FDR are shown for the high severity  
1095 group and the low severity group, with the latter divided into high and low neutralizers. Sixteen  
1096 out of the 20 proteins (left) show no significant difference between non-severe high versus low  
1097 neutralizers. Three proteins (middle-right) show levels in the low severity, high neutralizer  
1098 group which are intermediate between participants with high severity and low severity and low  
1099 neutralization. Levels of the remaining one protein show no significant difference between  
1100 participants with severe disease and high neutralizers with non-severe disease. p-values by  
1101 the Kruskal-Wallis test with multiple hypothesis correction between group values per protein.

1102

1103 **Figure S1: Comparison of neutralization capacity of high neutralizers with low severity**  
1104 **to participants with high disease severity.** The y-axis shows FRNT<sub>50</sub>, with bar and error  
1105 bars representing the geometric mean and geometric standard deviation of each group. The  
1106 horizontal dashed red line marks the limit of quantification (the inverse of the highest plasma  
1107 concentration used). p-value by the non-parametric Mann-Whitney test.

1108

1109 **Figure S2: Overlap of comorbidities and requirement for supplemental oxygen in high**  
1110 **versus low neutralizers.** Participants not requiring supplemental oxygen and having neither  
1111 diabetes nor hypertension are marked in blue, those requiring supplemental oxygen but  
1112 without diabetes or hypertension are in red, participants with diabetes or hypertension  
1113 comorbidities only are in yellow, and those requiring both supplemental oxygen and with  
1114 diabetes or hypertension comorbidities are in green. Inset shows relative frequencies of the  
1115 four groups in high versus low neutralizers.


1116

1117 **Figure S3: Significantly differentially expressed proteins in the training set.** Volcano  
1118 plots show fold change versus false discovery rate (FDR) values for each protein. The x-axis  
1119 represents the log fold-change between the mean protein level values in the group of high



1120 versus low neutralizers or high versus low disease severity. Y-axis is the  $-\log_{10}$  transformed  
1121 FDR. The vertical lines indicate  $\pm 1.5$ -fold change and the horizontal line FDR=0.05.  
1122 Significantly differentially expressed proteins are labeled in red (upregulated) or blue  
1123 (downregulated). The proteins showing highest predictive value in the model are highlighted  
1124 in purple.

1125




**Figure 1: Study design and timeline.** Study participants were enrolled in the first South African SARS-CoV-2 infection wave between March and October 2020, where enrollment was a median of 6 days post-diagnosis. At enrollment, disease severity was assessed by whether a participant required supplemental oxygen. During this visit, a blood draw was performed, and blood plasma used for proteomic analysis using SomaScan proteomics. At 32 days post-diagnosis, a second blood draw was performed, and blood plasma was used in a live virus neutralization assay against ancestral SARS-CoV-2 to assess neutralization capacity.

**Table 1: Participant characteristics and comparison of non-severe vs severe groups.**


<b>Parameter</b>	<b>All</b>	<b>Non-severe</b>	<b>Severe</b>	<b>p-value</b>
n	72	55	17	
Days diag. to enrol., median (IQR)	6 (4 - 8)	6 (4 - 8)	6 (5 - 7)	0.87
Days diag. to neut. sample, median (IQR)	32 (17 - 35)	30 (16 - 35)	33 (28 - 34)	0.22
Age in years, median (IQR)	42 (34 - 50)	42 (32 - 50)	40 (36 - 55)	0.31
People living with HIV, n (%)	34 (47)	25 (45)	9 (53)	0.78
Sex, male (%)	22 (31)	15 (27)	7 (41)	0.37
CD4 at enrol., median (IQR)	590 (340 - 940)	700 (470 - 1100)	380 (270 - 590)	0.0072
CD4 at neut. sample, median (IQR)	830 (510 - 1100)	820 (530 - 1100)	840 (390 - 900)	0.43
NLR at enrol., median (IQR)	2 (1.2 - 4.1)	1.9 (1.2 - 2.5)	4.2 (1.3 - 7.5)	0.043
NLR at neut. sample, median (IQR)	1.6 (1.2 - 2.1)	1.6 (1.2 - 2.1)	1.5 (1.2 - 1.9)	0.77
D614G FRNT <sub>50</sub> , geomean	230	150	900	0.00052

**Table 2: Participant numbers in neutralization-severity combinations.**


	Non-severe	Severe	Sum
Low neutralization	33	3	36
High neutralization	22	13	35
Sum	55	16	71




**Figure 2: Neutralization capacity associates with disease severity but not HIV status.** (A) Participants were divided into high and low neutralizers based on whether the participant's plasma showed higher or lower neutralizing capacity relative to the median neutralization  $FRNT_{50}$  of all participants. For all plots, y-axis shows  $FRNT_{50}$ , with bar and error bars representing the geometric mean and geometric standard deviation of each group. The horizontal dashed red line marks the limit of quantification (the inverse of the highest plasma concentration used). (B) Participants in the high and low neutralization groups who required supplemental oxygen (red points). Inset shows frequency of participants on supplemental oxygen in each group ( $p=0.0046$  by Fisher's exact test). (C) High and low neutralizers who had a neutrophil to lymphocyte ratio (NLR) greater than 6. Inset: frequency of high NLR in each group ( $p=0.011$  by Fisher's exact test). (D) High and low neutralizers who had a comorbidity of diabetes, hypertension, or both. Inset: frequency of comorbidities in each group ( $p=0.00018$  by Fisher's exact test). (E) High and low neutralizers who were male. Inset: frequency of males in each group ( $p=0.042$  by Fisher's exact test). (F) High and low neutralizers who were people living with HIV (PLWH). Inset: frequency of PLWH in each group (not significant by Fisher's exact test). (G) Univariate and (H) multivariate logistic regression odds ratios for odds of having a high neutralization response.



**Figure 3: Differentially expressed proteins in neutralization and disease severity.** Volcano plots show fold-change versus false discovery rate (FDR) values for each protein in two comparisons: (A) High neutralizers compared to low neutralizers; (B) severe versus non-severe disease. The x-axis represents the log fold-change between the mean protein level values in the group of high versus low neutralizers or high versus low disease severity. Y-axis is the  $-\log_{10}$  transformed FDR. The vertical lines indicate  $\pm 1.5$ -fold change and the horizontal line FDR=0.05. Significantly differentially expressed proteins are labeled in red (upregulated), blue (downregulated), and green (shared between responses). (C) Venn diagram showing the number of differentially expressed proteins associated with neutralization capacity and disease severity and common to both.




**Figure 4: Significantly regulated pathways for neutralization and disease severity.** Gene Set Enrichment Analysis (GSEA) results for significantly up or downregulated pathways in participants with high versus low neutralization capacity and those with severe versus non-severe disease. The x-axis represents the Normalized Enrichment Score (NES). Each circle represents a pathway, with the size of the circle corresponding to the  $-\log_{10}$  transformed FDR value, with larger circles indicating higher significance. Purple circles represent pathways enriched in the high neutralization group and orange circles represent pathways enriched in the severe disease group. One pathway (fatty acid metabolism) is shared between both groups.




**Figure 5: Top differentially expressed proteins in the neutralization response show similar expression in high neutralizers regardless of disease severity.** Median Z-score normalized protein levels of the top 20 differentially expressed proteins by FDR are shown for the high neutralizers with severe disease, high neutralizers with non-severe disease, and low neutralizers. Fourteen out of the 20 proteins (left) show no significant difference between the high neutralizers with severe disease versus high neutralizers with non-severe disease. Six proteins (right) show significantly higher levels in high neutralizers with severe disease relative to high neutralizers with non-severe disease. However, the levels of these proteins in low neutralizers are significantly lower still. p-values by the Kruskal-Wallis test with multiple hypothesis correction between group values per protein. Outliers with an absolute normalized expression  $> 3$  are included in the analysis but excluded from the plot.







**Figure 6: Predictive models classifying participants into high versus low neutralization groups.** Shown are receiver operating characteristic (ROC) curves for (A) multivariate (HSPA8+FAP+MLN), (B) HSPA8, (C) FAP, and (D) MLN. Areas Under the Curve (AUC) were 0.91 (multivariate), 0.86 (HSPA8), 0.84 (FAP), and 0.79 (MLN). Dashed diagonal line represents the performance of a random classifier with AUC=0.50.




**Figure 7: Top differentially expressed proteins in the disease severity response show similar expression regardless of neutralization capacity.** Median Z-score normalized protein levels of the top 20 differentially expressed proteins by FDR are shown for the high severity group and the low severity group, with the latter divided into high and low neutralizers. Sixteen out of the 20 proteins (left) show no significant difference between non-severe high versus low neutralizers. Three proteins (middle-right) show levels in the low severity, high neutralizer group which are intermediate between participants with high severity and low severity and low neutralization. Levels of the remaining one protein show no significant difference between participants with severe disease and high neutralizers with non-severe disease. p-values by the Kruskal-Wallis test with multiple hypothesis correction between group values per protein. Outliers with an absolute normalized expression  $> 3$  are included in the analysis but excluded from the plot.



**Figure S1: Comparison of neutralization capacity of high neutralizers with low severity to participants with high disease severity.** The y-axis shows  $FRNT_{50}$ , with bar and error bars representing the geometric mean and geometric standard deviation of each group. The horizontal dashed red line marks the limit of quantification (the inverse of the highest plasma concentration used). p-value by the non-parametric Mann-Whitney test.



**Figure S2: Overlap of comorbidities and requirement for supplemental oxygen in high versus low neutralizers.** Participants not requiring supplemental oxygen and having neither diabetes nor hypertension are marked in blue, those requiring supplemental oxygen but without diabetes or hypertension are in red, participants with diabetes or hypertension comorbidities only are in yellow, and those requiring both supplemental oxygen and with diabetes or hypertension comorbidities are in green. Inset shows relative frequencies of the four groups in high versus low neutralizers.



**Figure S3: Significantly differentially expressed proteins in the training set.** Volcano plots show fold change versus false discovery rate (FDR) values for each protein. The x-axis represents the log fold-change between the mean protein level values in the group of high versus low neutralizers or high versus low disease severity. Y-axis is the  $-\log_{10}$  transformed FDR. The vertical lines indicate  $\pm 1.5$ -fold change and the horizontal line FDR=0.05. Significantly differentially expressed proteins are labeled in red (upregulated) or blue (downregulated). The proteins showing highest predictive value in the model are highlighted in purple.

**Table S1:** Logistic regression analysis results.

	Univariate		Multivariate	
	OR (95% CI)	p-value	OR (95% CI)	p-value
Supplemental O <sub>2</sub>	6.81 (1.92; 32.3)	0.00604	8.04 (1.8; 47)	0.0105
Comorbidities	9.78 (2.81; 46.2)	0.00102	7.61 (1.87; 40.2)	0.00781
High NLR	7.08 (1.68; 48.9)	0.0169	3.64 (0.571; 31.5)	0.19
Male	3.27 (1.16; 9.99)	0.0296	2.66 (0.686; 11)	0.162
PLWH	0.554 (0.21; 1.43)	0.224	0.476 (0.131; 1.6)	0.238